METHODS FOR EPITYPE ENRICHED PCR SCREENING CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No.63/376,894 filed September 23, 2022, the entire disclosure of which is hereby incorporated by reference in its entirety for all purposes. BACKGROUND [0002] DNA methylation is an epigenetic process by which a methyl group is added to DNA. This typically occurs at the C5 position of a cytosine to form 5-methylcytosine. DNA methylation can change the activity of DNA, e.g., by repressing gene transcription, and functions in many biological processes including genomic imprinting, X-chromosome inactivation, repression of transposable elements, aging, and carcinogenesis. Abnormal DNA methylation is associated with the development of health conditions, such as cancer. CpG islands can become abnormally methylated, with hypomethylation linked to chromosomal instability and hypermethylation associated with promoters and oncogene suppressor silencing. [0003] Differential DNA methylation can result in various patterns of methylation across numerous CpG sites. However, accurately detecting these various patterns of methylation, at the single nucleotide base resolution level, is challenging. Accordingly, there is a need for improved methods for detecting patterns of DNA methylation at the single nucleotide base level. Assessment of DNA methylation states can be used to predict risk for developing certain health conditions, such as cancer. SUMMARY [0004] Disclosed herein are methods and compositions useful for determining nucleic acid epitypes for subjects. The determination of nucleic acid epitypes may be useful for screening subjects who may be at risk for various health conditions (e.g., cancer). A nucleic acid epitype can be determined using a sample obtained from a subject. In various embodiments, determining a nucleic acid epitype using the sample can be useful for determining whether the subject is at risk for or not at risk for the health condition. In various embodiments, determining a nucleic acid epitype using the sample is useful for detecting circulating tumor DNA in the subject. [0005] Disclosed herein is a method of detecting a nucleic acid epitype, comprising: providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated; contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template; and detecting the nucleic acid epitype by detecting the nucleic acid epitype probe that hybridized to the nucleic acid template. In various embodiments, detecting the nucleic acid epitype probe comprises sequencing the nucleic acid epitype probe to determine the identity of the nucleic acid epitype. In various embodiments, each of the one or more CpG sites are selected from a CpG site in a CpG island (CGI) shown in any of Tables 1-4. In various embodiments, detecting the nucleic acid epitype comprises determining a methylation status of the nucleic acid epitype based on the detected nucleic acid epitype probe that hybridized to the nucleic acid template. In various embodiments, the methylation status of the nucleic acid epitype is one of non-methylated, partially methylated, or fully methylated. [0006] In various embodiments, contacting the nucleic acid template derived from converted cell-free DNA with the nucleic acid epitype probe occurs in the presence of a hybridization solution that selectively raises the stability of A:T base pairs to substantially the same stability of G:C base pairs. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC). In various embodiments, the nucleic acid epitype probe comprises a binding moiety that binds to a solid support. In various embodiments, the binding moiety comprises a biotin moiety. In various embodiments, the nucleic acid epitype probe comprises a detection moiety. In various embodiments, the detection moiety comprises a fluorescent tag. In various embodiments, the nucleic acid epitype probe comprises a barcode. [0007] In various embodiments, methods disclosed herein further comprise isolating the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises exposing the binding moiety to the solid support, and separating the solid support from non-specifically associated nucleic acids. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises performing a streptavidin bead pulldown. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe further comprises enriching for the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, enriching for the nucleic acid template hybridized to the nucleic acid epitype probe further comprises performing a wash to remove non-specifically associated nucleic acids. [0008] In various embodiments, methods disclosed herein further comprise: subsequent to isolating the nucleic acid template hybridized to the nucleic acid epitype probe and prior to detecting the nucleic acid epitype, dissociating the nucleic acid epitype probe from the nucleic acid template. In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to a temperature between 40 ^o C and 100 ^o C, between 45 ^o C and 95 ^o C, between 50 ^o C and 90 ^o C, between 55 ^o C and 90 ^o C, between 60 ^o C and 85 ^o C, between 65 ^o C and 80 ^o C, between 70 ^o C and 75 ^o C, between 45 ^o C and 75 ^o C, between 50 ^o C and 70 ^o C, or between 55 ^o C and 65 ^o C. In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to a pH between 7.0 and 13.0, between 7.5 and 12.5, between 8.0 and 12.0, between 8.5 and 11.5, between 9.0 and 11.0, between 9.5 and 10.5, between 9.8 and 10.2, between 7.0 and 10.0, between 7.5 and 9.5, between 8.0 and 9.0, between 10.0 and 13.0, between 10.5 and 12.5, or between 11.0 and 12.0. In various embodiments, methods disclosed herein further comprise pooling the dissociated nucleic acid epitype probe with one or more other nucleic acid epitype probes, wherein the one or more other nucleic acid epitype probes were dissociated from other nucleic acid templates. In various embodiments, the epitype probe and the one or more other nucleic acid epitype probes each comprise different barcodes. [0009] In various embodiments, methods disclosed herein further comprise amplifying the dissociated nucleic acid epitype probe. In various embodiments, methods disclosed herein further comprise demultiplexing sequencing data from the nucleic acid epitype probe and the one or more other nucleic acid epitype probes using the differing barcodes of the nucleic acid epitype probe and one or more other nucleic acid epitype probes. In various embodiments, methods disclosed herein further comprise: prior to providing the nucleic acid epitype probe, performing conversion of cell-free DNA obtained from the biological sample of the subject. In various embodiments, the converted cell-free DNA comprises bi-sulfite converted cell-free DNA. In various embodiments, the biological sample of the subject is a blood sample. [0010] In various embodiments, methods disclosed herein further comprise: providing one or more additional nucleic acid epitype probes, wherein one of the additional nucleic acid epitype probe comprises a sequence that differs from the sequence of the nucleic acid epitype probe by one nucleotide. In various embodiments, the one nucleotide difference is a G Æ A substitution. In various embodiments, the one or more additional nucleic acid epitype probes do not hybridize with the nucleic acid template. In various embodiments, the one or more additional nucleic acid epitype probes comprise (2 ^{^} െ 1) additional nucleic acid epitype probes, wherein X represents a total number of CpG sites in a sequence of the cell-free DNA. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises one or more of a biotin moiety, a fluorescent tag, or a barcode. In various embodiments, the nucleic acid epitype probe and at least one of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprise a common barcode sequence. In various embodiments, providing the nucleic acid epitype probe and providing one or more additional nucleic acid epitype probes occurs simultaneously. [0011] Additionally disclosed herein is a method of detecting a nucleic acid epitype, comprising: providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated; contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe in the presence of a hybridization solution that selectively raises the stability of A:T base pairs to substantially the same stability of G:C base pairs, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template; amplifying the nucleic acid template using the nucleic acid epitype probe as an amplification primer, and detecting the nucleic acid epitype by detecting a signal indicative of presence of an amplification product generated by amplifying the nucleic acid template. [0012] In various embodiments, amplifying the nucleic acid template comprises performing polymerase chain reaction. In various embodiments, detecting the signal indicative of the amplification product comprises detecting a fluorescent signal. In various embodiments, each of the one or more CpG sites are selected from a CpG site in a CpG island (CGI) shown in any of Tables 1-4. In various embodiments, detecting the nucleic acid epitype further comprises determining a methylation status of the nucleic acid epitype based on the presence of the amplification product. In various embodiments, the methylation status of the nucleic acid epitype is one of non-methylated, partially methylated, or fully methylated. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC). In various embodiments, detecting the nucleic acid epitype further comprises determining a number of amplification cycles until the signal indicative of presence of the amplification product was detected. In various embodiments, detecting the nucleic acid epitype further comprises comparing the number of amplification cycles to a number of amplification cycles until a corresponding signal was detected in a control sample. [0013] Additionally disclosed is a method for detecting circulating tumor DNA in a biological sample of a subject, the method comprising: providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated; contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe in the presence of a hybridization solution that selectively raises the stability of A:T base pairs to substantially the same stability of G:C base pairs, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template; and detecting the circulating tumor DNA by detecting the nucleic acid epitype probe that hybridized to the nucleic acid template. [0014] In various embodiments, detecting the nucleic acid epitype probe comprises sequencing the epitype probe to determine the identity of the nucleic acid epitype. In various embodiments, each of the one or more CpG sites are selected from a CpG site in a CpG island (CGI) shown in any of Tables 1-4. In various embodiments, detecting the nucleic acid epitype comprises determining a methylation status of the nucleic acid epitype based on the detected nucleic acid epitype probe that hybridized to the nucleic acid template. In various embodiments, the methylation status of the nucleic acid epitype is one of non-methylated, partially methylated, or fully methylated. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC). In various embodiments, the nucleic acid epitype probe comprises a binding moiety that binds to a solid support. In various embodiments, the binding moiety comprises a biotin moiety. In various embodiments, the nucleic acid epitype probe comprises a detection moiety. In various embodiments, the detection moiety comprises a fluorescent tag. In various embodiments, the nucleic acid epitype probe comprises a barcode. [0015] In various embodiments, methods disclosed herein further comprise isolating the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises exposing the binding moiety to the solid support, and separating the solid support from non-specifically associated nucleic acids. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises performing a streptavidin bead pulldown. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe further comprises enriching for the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, methods disclosed herein enriching for the nucleic acid template hybridized to the nucleic acid epitype probe further comprises performing a wash to remove non- specifically associated nucleic acids. [0016] In various embodiments, methods disclosed herein further comprise: subsequent to isolating the nucleic acid template hybridized to the nucleic acid epitype probe and prior to detecting the nucleic acid epitype, dissociating the nucleic acid epitype probe from the nucleic acid template. In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to a temperature between 40 ^o C and 100 ^o C, between 45 ^o C and 95 ^o C, between 50 ^o C and 90 ^o C, between 55 ^o C and 90 ^o C, between 60 ^o C and 85 ^o C, between 65 ^o C and 80 ^o C, between 70 ^o C and 75 ^o C, between 45 ^o C and 75 ^o C, between 50 ^o C and 70 ^o C, or between 55 ^o C and 65 ^o C. In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to a pH between 7.0 and 13.0, between 7.5 and 12.5, between 8.0 and 12.0, between 8.5 and 11.5, between 9.0 and 11.0, between 9.5 and 10.5, between 9.8 and 10.2, between 7.0 and 10.0, between 7.5 and 9.5, between 8.0 and 9.0, between 10.0 and 13.0, between 10.5 and 12.5, or between 11.0 and 12.0. In various embodiments, methods disclosed herein further comprise pooling the dissociated nucleic acid epitype probe with one or more other nucleic acid epitype probes, wherein the one or more other nucleic acid epitype probes were dissociated from other one or more other nucleic acid templates. In various embodiments, the epitype probe and the one or more other nucleic acid epitype probes each comprise different barcodes. [0017] In various embodiments, methods disclosed herein further comprise amplifying the dissociated nucleic acid epitype probe. In various embodiments, methods disclosed herein further comprise demultiplexing sequencing data from the nucleic acid epitype probe and the one or more other nucleic acid epitype probes using the differing barcodes of the nucleic acid epitype probe and one or more other nucleic acid epitype probes. In various embodiments, methods disclosed herein further comprise: prior to providing the nucleic acid epitype probe, performing conversion of cell-free DNA obtained from the biological sample of the subject. In various embodiments, the converted cell-free DNA comprises bi-sulfite converted cell-free DNA. In various embodiments, the biological sample of the subject is a blood sample. [0018] In various embodiments, methods disclosed herein further comprise: providing one or more additional nucleic acid epitype probes, wherein one of the additional nucleic acid epitype probe comprises a sequence that differs from the sequence of the nucleic acid epitype probe by one nucleotide. In various embodiments, the one nucleotide difference is a G A substitution. In various embodiments, the one or more additional nucleic acid epitype probes do not hybridize with the nucleic acid template. In various embodiments, the one or more additional nucleic acid epitype probes comprise (2 ^{^} െ 1) additional nucleic acid epitype probes, wherein X represents a total number of CpG sites in a sequence of the cell-free DNA. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises one or more of a biotin moiety, a fluorescent tag, or a barcode. In various embodiments, the nucleic acid epitype probe and at least one of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprise a common barcode sequence. In various embodiments, providing the nucleic acid epitype probe and providing one or more additional nucleic acid epitype probes occurs simultaneously. [0019] Additionally disclosed herein is a method for detecting circulating tumor DNA in a biological sample of a subject, the method comprising: providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated; contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe in the presence of a hybridization solution that selectively raises the stability of A:T base pairs to substantially the same stability of G:C base pairs, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template; amplifying the nucleic acid template using the nucleic acid epitype probe as an amplification primer, and detecting the circulating tumor DNA by detecting a signal indicative of presence of an amplification product generated by amplifying the nucleic acid template. [0020] In various embodiments, amplifying the nucleic acid template comprises performing polymerase chain reaction. In various embodiments, detecting the signal indicative of the amplification product comprises detecting a fluorescent signal. In various embodiments, each of the one or more CpG sites are selected from a CpG site in a CpG island (CGI) shown in any of Tables 1-4. In various embodiments, detecting the nucleic acid epitype further comprises determining a methylation status of the nucleic acid epitype based on the presence of the amplification product. In various embodiments, the methylation status of the nucleic acid epitype is one of non-methylated, partially methylated, or fully methylated. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC). In various embodiments, detecting the nucleic acid epitype further comprises determining a number of amplification cycles until the signal indicative of presence of the amplification product was detected. In various embodiments, detecting the nucleic acid epitype further comprises comparing the number of amplification cycles to a number of amplification cycles until a corresponding signal was detected in a control sample. [0021] Additionally disclosed herein is a composition comprising: a nucleic acid template derived from bisulfite converted cell-free DNA obtained from a biological sample of a subject, wherein prior to conversion, the cell-free DNA comprises a sequence between 50-500 nucleotides, between 75-400 nucleotides, between 100-300 nucleotides, between 125-250 nucleotides, or between 150-200 nucleotides of a CpG island (CGI), wherein between 0 and X cytosines of the sequence of the cell-free DNA are converted to a uracil in the nucleic acid template, wherein X represents a total number of CpG sites in the sequence of the cell-free DNA; and a nucleic acid epitype probe hybridized to the nucleic acid template, wherein the nucleic acid epitype probe comprises a sequence complementary to the sequence of the nucleic acid template. [0022] Additionally disclosed herein is a composition comprising a nucleic acid epitype probe comprising: a nucleic acid sequence complementary to a sequence of a nucleic acid template derived from bisulfite converted cell-free DNA obtained from a biological sample of a subject, wherein prior to conversion, the cell-free DNA comprises a sequence between 50-500 nucleotides, between 75-400 nucleotides, between 100-300 nucleotides, between 125-250 nucleotides, or between 150-200 nucleotides of a CpG island (CGI), and a binding moiety that binds to a solid support, a detection moiety, and/or a barcode. [0023] In various embodiments, the CpG island is selected from a CpG island shown in Tables 1-4. In various embodiments, the composition further comprises a hybridization solution. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC). In various embodiments, the nucleic acid epitype probe comprises a binding moiety that binds to a solid support. In various embodiments, the binding moiety comprises a biotin moiety. In various embodiments, the nucleic acid epitype probe comprises a detection moiety. In various embodiments, the detection moiety comprises a fluorescent tag. In various embodiments, the nucleic acid epitype probe comprises a barcode. In various embodiments, the composition further comprises a bead non-covalently linked to the nucleic acid template. In various embodiments, the composition further comprises one or more additional nucleic acid epitype probes, wherein one of the additional nucleic acid epitype probe comprises a sequence that differs from the sequence of the nucleic acid epitype probe by one nucleotide. In various embodiments, the one nucleotide difference is a G Æ A substitution. In various embodiments, the one or more additional nucleic acid epitype probes are not hybridized with the nucleic acid template. In various embodiments, the one or more additional nucleic acid epitype probes comprise (2 ^{^} െ 1) additional nucleic acid epitype probes, wherein X represents a total number of CpG sites in the sequence of corresponding cell-free DNA. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises a biotin moiety. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises a fluorescent tag. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises a barcode. BRIEF DESCRIPTION OF THE DRAWINGS [0024] These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description and accompanying drawings. It is noted that wherever practicable, similar or like reference numbers may be used in the figures and may indicate similar or like functionality. For example, a letter after a reference numeral, such as “nucleic acid epitype probe 310A,” indicates that the text refers specifically to the element having that particular reference numeral. A reference numeral in the text without a following letter, such as “nucleic acid epitype probe 310,” refers to any or all of the elements in the figures bearing that reference numeral (e.g., “nucleic acid epitype probe 310” in the text refers to reference numerals “nucleic acid epitype probe 310A” and/or “nucleic acid epitype probe 310B” in the figures). [0025] Figure (FIG.) 1 depicts an overall flow process for detecting a nucleic acid epitype, in accordance with an embodiment. [0026] FIG.2A depicts an example conversion of nucleic acids, in accordance with an embodiment. [0027] FIG.2B shows the results of nitrite conversion on select nucleotides, in accordance with a second embodiment. Figure adapted from Li et al. (2022) Genome Biology 23:122. [0028] FIG.3A depicts an example provision of nucleic acid epitype probes, in accordance with an embodiment. [0029] FIG.3B depicts example hybridization of a nucleic acid epitype probe to a nucleic acid template, in accordance with an embodiment. [0030] FIGs.4A, 4B, and 4C depict example nucleic acid epitype probes, in accordance with different embodiments. [0031] FIG.5A depicts enrichment of the nucleic acid epitype probe hybridized to the nucleic acid template, in accordance with an embodiment. [0032] FIG.5B depicts an example dissociation of the nucleic acid epitype probe from the nucleic acid template, in accordance with an embodiment. [0033] FIG.5C depicts subsequent processing of a nucleic acid epitype probe, including amplification and sequencing of the nucleic acid epitype probe, in accordance with an embodiment. [0034] FIG.6 shows an example process for amplifying and detecting a nucleic acid epitype, in accordance with an embodiment. [0035] FIG.7 shows an example process for detecting a nucleic acid epitype. DETAILED DESCRIPTION Definitions [0036] Terms used in the claims and specification are defined as set forth below unless otherwise specified. [0037] The term “about” refers to a value that is within 10% above or below the value being described. For example, the term “about 5 nM” indicates a range of from 4.5 nM to 5.5 nM. [0038] The terms “subject,” “patient,” and “individual” are used interchangeably and encompass a cell, tissue, or organism, human or non-human, male or female. [0039] The term “sample” can include a single cell or multiple cells or fragments of cells or an aliquot of body fluid, such as a blood sample, taken from a subject, by means including venipuncture, excretion, ejaculation, massage, biopsy, needle aspirate, lavage sample, scraping, surgical incision, or intervention or other means known in the art. Examples of an aliquot of body fluid include amniotic fluid, aqueous humor, bile, lymph, breast milk, interstitial fluid, blood, blood plasma, cerumen (earwax), Cowper’s fluid (pre-ejaculatory fluid), chyle, chyme, female ejaculate, menses, mucus, saliva, urine, vomit, tears, vaginal lubrication, sweat, serum, semen, sebum, pus, pleural fluid, cerebrospinal fluid, synovial fluid, intracellular fluid, and vitreous humour. [0040] The term “epitype” or “nucleic acid epitype” refer to a region of nucleic acid (i.e., DNA or RNA) containing an epigenetic variation. For example, the epigenetic variation could be methylation or non-methylation of one or more nucleotides in a region of nucleic acid. For instance, in some embodiments the nucleotide that could be methylated or non-methylated may be a cytidine, e.g., at a CpG site (e.g., the nucleotide could be 5-methylcytidine or cytidine). Exemplary CpG sites may be found in, for example, CpG islands (CGIs) shown in Tables 1-4. CpG islands (CGIs) may be regions having a length greater than 200 bp, a GC content greater than 50% and a ratio of observed to expected CpG greater than 0.6. CpG islands are often found in promoter regions, where methylation is associated with transcriptional repression. Generally, a nucleic acid epitype containing one or more CpG sites may have a methylation pattern, such as any of fully non-methylated (e.g., none of the CpG sites in the epitype are methylated), partially methylated (e.g., at least one but not all of the CpG sites in the epitype are methylated), or fully methylated (e.g., all of the CpG sites in the epitype are methylated). In other embodiments, the nucleotide that could be methylated or non-methylated may be adenosine (e.g., the nucleotide could be N6-methyladenosine or adenosine). Overview [0041] Disclosed herein are methods and compositions useful for determining nucleic acid epitypes. As referred to herein, a nucleic acid epitype refers to a region of nucleic acid containing one or more epigenetic variations, such as methylation or non-methylation of one or more nucleotides, e.g., at cytidine residues within CpG sites. Thus, in various embodiments, methods and compositions disclosed herein are useful for determining statuses (e.g., methylation statuses) of the one or more CpG sites in the nucleic acid epitype. For example, methods and compositions disclosed herein can be used to determine whether a nucleic acid epitype includes one or more CpG sites that are fully non-methylated, partially methylated, or fully methylated. In various embodiments, determining a nucleic acid epitype can be useful for performing screens, e.g., for determining whether the sample obtained from a subject is at risk or not at risk for a health condition. In various embodiments, determining a nucleic acid epitype can be useful for detecting presence or absence of circulating tumor DNA in the sample obtained from a subject. [0042] In particular embodiments, disclosed herein are compositions comprising a nucleic acid epitype probe. In various embodiments, a nucleic acid epitype probe is designed to be complementary to a sequence of a converted nucleic acid epitype (e.g., bisulfite-converted nucleic acid epitype), the sequence comprising one or more CpG sites that, prior to conversion, were one of non-methylated, partially methylated, or fully methylated. In various embodiments, different nucleic acid epitype probes can be designed to be fully complementary to the sequence a converted nucleic acid epitype, depending on the prior methylation statuses of the one or more CpG sites of the converted nucleic acid epitype. For example, given ^ CpG sites in the converted nucleic acid epitype, 2 ^{^} different nucleic acid epitype probes can be designed such that one of the different nucleic acid epitype probes is fully complementary to the sequence of the ^ CpG sites of the converted nucleic acid epitype. Thus, by detecting the nucleic acid epitype probe that hybridized with the sequence of the converted nucleic acid epitype, the methylation statuses of the CpG sites of the nucleic acid epitype can be detected. [0043] FIG.1 depicts an overall flow process 100 for detecting a nucleic acid epitype, in accordance with an embodiment. Although FIG.1 shows the flow process in relation to a single subject 110, in various embodiments, the flow process can be performed for more than a single subject 110 (e.g., for thousands, millions, tens of millions, or hundreds of millions of subjects). [0044] As shown in FIG.1, step 115 involves obtaining a sample from the subject 110. In various embodiments, a sample is any of a blood sample, a stool sample, a urine sample, a mucous sample, or a saliva sample. In particular embodiments, a sample obtained from the subject 110 is a blood sample. The sample can be obtained by the subject or by a third party, e.g., a medical professional. Examples of medical professionals include physicians, emergency medical technicians, nurses, first responders, psychologists, phlebotomists, medical physics personnel, nurse practitioners, surgeons, dentists, and any other medical professional as would be known to one skilled in the art. In various embodiments, the one or more samples can be obtained from the subject 110 by a reference lab. [0045] In various embodiments, the sample obtained from the subject is a liquid biopsy sample. In various embodiments, the liquid biopsy sample may include various biomarkers, examples of which include proteins, metabolites, and/or nucleic acids. In particular embodiments, the liquid biopsy sample includes cell-free DNA (cfDNA). In particular embodiments, the cfDNA includes genomic sequences corresponding to CpG islands (CGIs) for which methylation states are informative of a health condition. In various embodiments, the cfDNA can be derived from tumor cells and is referred to herein as circulating tumor DNA (ctDNA). [0046] Step 120 involves converting the nucleic acid in the sample obtained from the subject. In various embodiments, converting the nucleic acid involves converting unmethylated nucleotides (e.g., cytosines) to another nucleotide (a “converted nucleotide”, as used herein). In various embodiments, methylated cytosines are protected from conversion (e.g., deamination) during the conversion step. This enables subsequent downstream differentiation of methylated cytosines and unmethylated cytosines for determining nucleic acid epitypes. Further details of step 120 are described herein. [0047] Although not shown in FIG.1, in various embodiments, after conversion of nucleic acids, the converted nucleic acids undergo library construction. In various embodiments, converted nucleic acids can undergo end-repairing and/or addition of library or sequencing adapters. In various embodiments, converted nucleic acids can undergo biotinylation (e.g., addition of biotin moieties to converted nucleic acids). In various embodiments, barcodes can be incorporated into converted nucleic acids, thereby enabling subsequent sample demultiplexing (e.g., demultiplexing to identify sources of converted nucleic acids or demultiplexing to identify a common source from converted nucleic acids). As used herein, a “nucleic acid template” refers to a nucleic acid derived from the converted nucleic acid (e.g., any of a nucleic acid derived from a converted nucleic acid that underwent library construction, end-repairing, addition of library or sequencing adapters, biotinylation, barcode addition, or any combination thereof). [0048] Step 125 involves providing nucleic acid epitype probes. In various embodiments, nucleic acid epitype probes are designed to interrogate the full range of possible CpG methylation statuses of a nucleic acid epitype. For example, given X CpG sites within a nucleic acid epitype (each CpG site having a status of either methylated or non-methylated), then the full range of possible CpG methylation statuses of the nucleic acid epitype is 2 ^{^} . Thus, in various embodiments, step 125 involves providing at least 2 ^{^} nucleic acid epitype probes to nucleic acid templates derived from the converted nucleic acid. The particular nucleic acid epitype probe that hybridizes with a sequence of the nucleic acid template is indicative of the methylation statuses of the X CpG sites within the nucleic acid epitype. Further details of step 125 are described herein. [0049] Step 130 involves processing a nucleic acid template derived from the converted that is hybridized to a nucleic acid epitype probe. In various embodiments, processing a nucleic acid template in step 130 involves isolating the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, processing a nucleic acid template in step 130 involves enriching for the nucleic acid template hybridized to the nucleic acid epitype probe. In various embodiments, processing a nucleic acid template in step 130 involves dissociating the nucleic acid epitype probe from the nucleic acid template. In various embodiments, processing a nucleic acid template in step 130 involves amplifying the nucleic acid epitype probe. In various embodiments, processing a nucleic acid template in step 130 involves amplifying the nucleic acid template using the nucleic acid epitype probe as a primer. Further details of step 130 are described herein. [0050] Step 135 involves detecting the nucleic acid epitype by detecting the nucleic acid epitype probe that hybridized to the nucleic acid template. In various embodiments, detecting the nucleic acid epitype probe involves amplifying and sequencing the nucleic acid epitype probe. By determining the sequence of the nucleic acid epitype probe, the complementary sequence of the nucleic acid epitype, including the sequences of the CpG sites of the nucleic acid epitype, can be determined. Thus, this enables detection of the nucleic acid epitype, including the methylation statuses of the CpG sites of the nucleic acid epitype. In various embodiments, detecting the nucleic acid epitype probe involves detecting a signal of the nucleic acid epitype probe, such as a fluorescent signal. For example, with real-time PCR, fluorescent dyes of nucleic acid epitype probes can be used to label generated amplicons derived from the nucleic acid template. Thus, detection of the signal (e.g., fluorescent signal) is indicative of the presence of the generated amplicons derived from the nucleic acid template. Further details of step 135 are described herein. [0051] In various embodiments, detecting the nucleic acid epitype is useful for determining whether a subject is not at risk for a health condition. For example, given particular methylation statuses of CpG sites in a nucleic acid epitype, a subject can be determined to be at risk or not at risk for a health condition. In various embodiments, subjects that have not been identified as not at risk of the health condition can undergo additional analysis (e.g., reflex test). For example, subjects not identified as not at risk can be candidate subjects who are selected for enrollment in a clinical trial. Thus, methods disclosed herein enable the accurate identification of individuals (from amongst a large patient population) who may be at risk of having a health condition and therefore, meet the eligibility criteria for enrollment in a clinical trial. Example methods for converting nucleic acids [0052] As discussed herein, step 120 in FIG.1 involves converting nucleic acids from the obtained sample. In various embodiments, converting nucleic acids includes treating the nucleic acids to capture methylation modifications. In various embodiments, converting nucleic acids involves converting one or more unmethylated nucleotides (e.g., cytosines) to another nucleotide (a “converted nucleotide”, as used herein), e.g., using chemical or enzymatic means. In certain embodiments, one or more unmethylated cytosines are converted to a nucleotide that pairs with adenine (e.g., the unmethylated cytosine may be converted to uracil). In certain embodiments, one or more unmethylated adenines are converted to a base that pairs with cytosine (e.g., the unmethylated adenine may be converted to inosine (I)). In certain embodiments, one or more methylated cytosines (e.g., a 5-methylcytosine (5mC)) is converted to a thymine, which pairs with adenine. In certain embodiments, methylated cytosines are protected from conversion (e.g., deamination) during the conversion step. [0053] After a nucleic acid has been treated to convert unmethylated, or, in some cases, methylated nucleotides, into another nucleotide, the nucleic acid may be amplified. During amplification, the converted nucleotide pairs with its complementary nucleotide, and in the next round of amplification, the complementary nucleotide pairs with a replacement nucleotide. For example, following the conversion of an unmethylated cytosine to a uracil, the nucleic acid may be amplified such that an adenine pairs with the uracil in the first round of replication, and in the second round of replication, the adenine pairs with a thymine. Accordingly, the thymine replaces the uracil in the original nucleic acid sequence, and is referred to herein as a “replacement nucleotide”. [0054] In certain aspects, conversion of the nucleic acids involves selectively deaminating nucleotides. FIG. 2 depicts an example conversion of nucleic acids, in accordance with an embodiment. Selective deamination refers to a process in which unmethylated cytosine residues are selectively deaminated over methylated cytosine (5-methylcytosine) residues. In certain embodiments, deamination of cytosine forms uracil, effectively inducing a C to T point mutation to allow for detection of methylated cytosines. Methods of deaminating cytosine are known in the art, and include chemical conversion (e.g., bisulfite conversion) and enzymatic conversion. In certain embodiments, the enzymatic conversion comprises subjecting the nucleic acid to TET2, which oxidizes methylated cytosines, thereby protecting them, and subsequent exposure to APOBEC, which converts unprotected (i.e., unmethylated) cytosines to uracils. [0055] In some embodiments, the conversion, for example, bisulfite conversion or enzymatic conversion, uses commercially available kits. Bisulfite conversion can be performed using commercially available technologies, such as EZ DNA Methylation-Gold, EZ DNAMethylation- Direct or an EZ DNAMethylation-Lighting kit (Zymo Research Corp (Irvine, California)) or EpiTect Fast available from Qiagen (Germantown, MD). In another example a kit such as APOBECSeq (NEBiolabs) or OneStep qMethyl-PCR Kit (Zymo Research Corp (Irvine, California)) is used. i. Bisulfite conversion [0056] Bisulfite conversion is performed on DNA by denaturation using high heat, preferential deamination (at an acidic pH) of unmethylated cytosines, which are then converted to uracil by desulfonation (at an alkaline pH). Methylated cytosines remain unchanged on the single- stranded DNA (ssDNA) product. [0057] In some embodiments the methods include treatment of the sample with bisulfite (e.g., sodium bisulfite, potassium bisulfite, ammonium bisulfite, magnesium bisulfite, sodium metabisulfite, potassium metabisulfite, ammonium metabisulfite, magnesium metabisulfite and the like). Unmethylated cytosine is converted to uracil through a three-step process during sodium bisulfite modification. As shown in FIG. 2, the steps are sulphonation to convert cytosine to cytosine sulphonate, deamination to convert cytosine sulphonate to uracil sulphonate and alkali desulphonation to convert uracil sulphonate to uracil. Conversion on methylated cytosine is much slower and is not observed at significant levels in a 4-16 hour reaction. (See Clark et al., Nucleic Acids Res., 22(15):2990-7 (1994).) If the cytosine is methylated it will remain a methylated cytosine. If the cytosine is unmethylated it will be converted to uracil. When the modified strand is copied, for example, through extension of a locus specific primer, a random or degenerate primer or a primer to an adaptor, a G will be incorporated in the interrogation position (opposite the C being interrogated) if the C was methylated and an A will be incorporated in the interrogation position if the C was unmethylated and converted to U. When the double stranded extension product is amplified those Cs that were converted to Us and resulted in incorporation of A in the extended primer will be replaced by Ts during amplification. Those Cs that were not converted (i.e., the methylated Cs) and resulted in the incorporation of G will be replaced by unmethylated Cs during amplification. ii. Enzymatic conversion [0058] In certain embodiments, the enzymatic treatment with a cytidine deaminase enzyme is used to convert cytosine to uracil. Enzymatic conversion can include an oxidation step, in which Tet methylcytosine dioxygenase 2 (TET2) catalyzes the oxidation of 5mC to 5hmC to protect methylated cytosines from conversion by subsequent exposure to a cytidine deaminase. Other protection steps known in the art can be used in addition to or in place of oxidation by TET2. After the oxidation step, the nucleic acid is treated with the cytidine deaminase to convert one or more unmethylated cytosines to uracils. As with bisulfite conversion, when the modified strand is copied, a G will be incorporated in the interrogation position (opposite the C being interrogated) if the C was methylated and an A will be incorporated in the interrogation position if the C was unmethylated. When the double stranded extension product is amplified those Cs that were converted to Us and resulted in incorporation of A in the extended primer will be replaced by Ts during amplification. Those Cs that were not modified and resulted in the incorporation of G will remain as C. [0059] In certain embodiments the cytidine deaminase may be APOBEC. In certain embodiments the cytidine deaminase includes activation induced cytidine deaminase (AID) and apolipoprotein B mRNA editing enzymes, catalytic polypeptide-like (APOBEC). In certain embodiments, the APOBEC enzyme is selected from the human APOBEC family consisting of: APOBEC-1 (Apo1), APOBEC-2 (Apo2), AID, APOBEC-3A, -3B, -3C, -3DE, -3F, -3G, -3H and APOBEC-4 (Apo4). In certain embodiments, the APOBEC enzyme is APOBEC-seq. iii. Nitrite Conversion [0060] In certain embodiments, nitrite treatment is used to deaminate adenine and cytosine. As shown in FIG.2B, deamination of an A results in conversion to an inosine (I), which is read by a polymerase as a G, whereas deamination of a methylated A (N ⁶ -methyladenine (6mA)) results in a nitrosylated 6mA (6mA-NO), which causes the base to be read by a polymerase as an A. Deamination of a C results in conversion to a uracil, which is read by a polymerase as a T, whereas deamination of a N ⁴ -methylcytosine (4mC) to 4mC-NO or a 5-methylcytosine (5mC) to a T causes the base to be read by a polymerase as a C or a T, respectively. For 5mC bases, the C to T ratio at the 5mC position is about 40% higher than other cytosine positions, allowing 5mC to be differentiated from C. (See, Li et al. (2022) Genome Biology 23:122.) Example provision of nucleic acid epitype probes [0061] As discussed herein, step 125 in FIG.1 involves providing nucleic acid epitype probes (e.g., providing nucleic acid epitype probes to nucleic acid templates derived from converted nucleic acids). In various embodiments, a nucleic acid epitype probe refers to a nucleic acid sequence that is complementary to a sequence of a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated. In various embodiments, a nucleic acid epitype probe comprises at least 50 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 350 nucleotides, at least 400 nucleotides, at least 450 nucleotides, at least 500 nucleotides, at least 550 nucleotides, at least 600 nucleotides, at least 650 nucleotides, at least 700 nucleotides, at least 750 nucleotides, at least 800 nucleotides, at least 850 nucleotides, at least 900 nucleotides, at least 950 nucleotides, or at least 1000 nucleotides. In various embodiments, a nucleic acid epitype probe comprises between 10 and 1000 nucleotides, between 20 and 900 nucleotides, between 30 and 800 nucleotides, between 40 and 700 nucleotides, between 50 and 600 nucleotides, between 60 and 500 nucleotides, between 70 and 400 nucleotides, between 80 and 300 nucleotides, between 90 and 200 nucleotides, between 100 and 190 nucleotides, between 110 and 180 nucleotides, between 120 and 170 nucleotides, between 130 and 160 nucleotides, or between 140 and 155 nucleotides. [0062] In various embodiments, a nucleic acid template is derived from cell-free DNA that has undergone conversion. In particular embodiments, a nucleic acid template is derived from bisulfite converted cell-free DNA (e.g., obtained from a biological sample of a subject). For example, a nucleic acid template may comprise bisulfite converted cell-free DNA that underwent library construction (e.g., addition of one or more adapters) and/or biotinylation. In various embodiments, a sequence of the bisulfite converted cell-free DNA may match a sequence of the nucleic acid template, wherein the nucleic acid template further includes one or more adapters and/or a binding moiety (e.g., a biotin moiety). In some embodiments, a sequence of the bisulfite converted cell-free DNA may not exactly match a sequence of the nucleic acid template. For example, in a scenario where the bisulfite converted cell-free DNA undergoes amplification, replacement nucleotides may be incorporated such that uracil nucleobases in the bisulfite converted cell-free DNA are replaced by thymine nucleobases in the nucleic acid template. [0063] In various embodiments, prior to undergoing conversion (e.g., bisulfite conversion), the cell-free DNA comprises a sequence between 50-500 nucleotides of a CpG island (CGI) shown in Tables 1-4. In various embodiments, the cell-free DNA comprises a sequence between 75-400 nucleotides, between 100-300 nucleotides, between 125-250 nucleotides, or between 150-200 nucleotides of a CpG island (CGI) shown in Tables 1-4. [0064] In various embodiments, the cell-free DNA may comprise a sequence with X total CpG sites. In various embodiments, a region of the cell-free DNA (e.g., a nucleic acid epitype) may comprise a sequence with X total CpG sites. In various embodiments, the number of CpG sites, X, within a nucleic acid epitype comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 CpG sites. In various embodiments, the number of CpG sites X within a nucleic acid epitype comprises at least 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1500, 2000, or 2500 CpG sites. [0065] In various embodiments, after the cell-free DNA undergoes conversion (e.g., bisulfite conversion), between 0 and X cytosines of the sequence of the cell-free DNA are converted to a uracil. Thus, the resulting nucleic acid template may have between 0 and X uracil bases that were converted from cytosines. [0066] Generally, a sufficient number of different epitype probes are designed and provided to interrogate the full range of possible methylation statuses of CpG sites of a nucleic acid epitype. For example, if there are X CpG sites within a nucleic acid epitype, which gives rise to 2 ^{^} possible CpG methylation statuses, then 2 ^{^} nucleic acid epitype probes are provided. In various embodiments, CpG sites are found in CpG islands (CGI) which are regions with high frequency of CpG sites. Example CGIs include, but are not limited to, the CGIs shown in the accompanying tables (referred to herein as Tables 1-4) which lists, for each CGI, its respective location in the human genome. Additional example CGIs are disclosed in WO2018209361 (see Table 1) and WO2022133315 (see Table 2 entitled “TOO Methylation Sites” and Table 3 entitled “Pan Cancer Methylation Sites”), each of which is hereby incorporated by reference in its entirety. [0067] As one example, the number of CpG sites, X, in a nucleic acid epitype is 1. Therefore, at least 2 different nucleic acid epitype probes are provided to differentiate between a nucleic acid template corresponding to a methylated CpG site and a nucleic acid template corresponding to a non-methylated CpG site. In various embodiments, X is 3. Therefore, at least 8 different nucleic acid epitype probes are provided to differentiate between the 8 different possible methylation statuses of the 3 CpG sites (e.g., 8 possible statuses include M/M/M, M/M/U, M/U/M, U/M/M, M/U/U, U/M/U, U/U/M, or U/U/U where “M” indicates methylated and “U” indicates unmethylated). Here, the specific nucleic acid epitype probe that is fully complementary with a sequence of the converted nucleic acid is indicative of the methylation statuses of the X CpG sites within the nucleic acid epitype. [0068] In various embodiments, one out of the 2 ^{^} different nucleic acid epitype probes will be fully complementary to a sequence of the nucleic acid template. Put another way, a nucleic acid epitype probe comprises a nucleic acid sequence complementary to a sequence of a nucleic acid template derived from bisulfite converted cell-free DNA obtained from a biological sample of a subject. Here, prior to conversion, the cell-free DNA comprises a sequence between 50-500 nucleotides, between 75-400 nucleotides, between 100-300 nucleotides, between 125-250 nucleotides, or between 150-200 nucleotides of a CpG island (CGI) shown in Tables 1-4. [0069] Generally, as described above, nucleic acid epitype probes disclosed herein include a sequence complementary to a nucleic acid epitype comprising X CpG sites with a particular methylation status. In various embodiments, nucleic acid epitype probes further include a binding moiety that binds to a solid support. In various embodiments, a binding moiety refers to a biotin moiety that can bind to a solid support (e.g., a solid bead) via a corresponding streptavidin moiety on the solid support. In various embodiments, a nucleic acid epitype probe comprises a detection moiety. In various embodiments, a detection moiety comprises a tag, such as a fluorescent tag. In various embodiments, a nucleic acid epitype probe comprises a barcode. Inclusion of a barcode sequence on nucleic acid epitype probes can enable subsequent demultiplexing. In various embodiments, each nucleic acid epitype probe includes a unique barcode that differs from other barcodes of other nucleic acid epitype probes. Use of unique barcodes enables demultiplexing of different probes. In various embodiments, nucleic acid epitype probes provided to nucleic acid templates from a common sample all have a common barcode, for example, which is different from the barcodes of probes provided to nucleic acid templates in other samples. This enables subsequent demultiplexing of nucleic acids from different samples. [0070] In various embodiments, providing nucleic acid epitype probes involves contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with a nucleic acid epitype probe. In various embodiments, the nucleic acid template contacts a nucleic acid epitype probe in the presence of a hybridization solution. As used herein, a hybridization solution selectively raises the stability of A:T base pairs to substantially the same stability of G:C base pairs. Given that the nucleic acid template is derived from converted nucleic acids, there are likely higher concentrations of A:T base pairs (due to C deaminating to U). Therefore, use of the hybridization solution to improve the stability of A:T base pairs can, in some circumstances, assist in improving the accuracy of detection of nucleic acid epitype probes. [0071] In particular embodiments, the hybridization solution comprises a quaternary ammonium salt, such as tetramethylammonium chloride (TMAC). In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC) at a concentration between 10 mM and 6 M. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC) at a concentration between 10 mM and 5 M, between 10 mM and 4 M, between 10 mM and 3 M, between 10 mM and 2 M, between 10 mM and 1 M, between 1 M and 6 M, between 2 M and 6 M, between 2 M and 5 M, between 2 M and 4 M, between 100 mM and 5 M, between 150 mM and 4 M, between 200 mM and 3 M, between 300 mM and 2 M, between 400 mM and 1 M, between 500 mM and 900 mM, between 600 mM and 800 mM, between 20 mM and 100 mM, between 30 mM and 90 mM, between 40 mM and 80 mM, between 50 mM and 70 mM, or between 55 mM and 65 mM. In various embodiments, the hybridization solution comprises tetramethylammonium chloride (TMAC) at a concentration of about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, about 500 mM, about 600 mM, about 700 mM, about 800 mM, about 900 mM, about 1 M, about 1.5 M, about 2 M, about 2.5 M, about 3 M, about 3.5 M, about 4 M, about 4.5 M, about 5M about 5.5 M, or about 6 M. [0072] In various embodiments, methods disclosed herein involve providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated; and contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template. In various embodiments, methods disclosed herein further involve providing one or more additional nucleic acid epitype probes, wherein one of the additional nucleic acid epitype probe comprises a sequence that differs from the sequence of the nucleic acid epitype probe by one nucleotide. In various embodiments, an additional nucleic acid epitype probe differs from the nucleic acid epitype probe by a single nucleotide, such as a G Æ A substitution. Due to the single nucleotide difference, the additional nucleic acid epitype probe does not hybridize with the nucleic acid template. In various embodiments, the one or more additional nucleic acid epitype probes comprise (2 ^{^} െ 1) additional nucleic acid epitype probes, wherein X represents a total number of CpG sites in a sequence of the cell-free DNA. In various embodiments, each of the (2 ^{^} െ 1) additional nucleic acid epitype probes comprises one or more of a biotin moiety, a fluorescent tag, or a barcode. In various embodiments, providing the nucleic acid epitype probe and providing one or more additional nucleic acid epitype probes occurs simultaneously. For example, the nucleic acid epitype probe and the one or more additional nucleic acid epitype probes can be substantially mixed together and then provided together e.g., to a nucleic acid template derived from converted cell-free DNA. [0073] Reference is now made to FIG.3A, which depicts an example provision of nucleic acid epitype probes, in accordance with an embodiment. FIG.3A depicts a nucleic acid template 305 derived from converted nucleic acids. In various embodiments, the nucleic acid template 305 previously underwent library construction. The nucleic acid template 305 may include one or more adapters, a biotin moiety, a barcode, or any combination thereof. [0074] Nucleic acid epitype probes 310 are provided to contact the nucleic acid template 305. FIG. 3A shows individual nucleic acid epitype probes (e.g., 310A, 310B, 310C, etc.). In total, there may be 2 ^{^} total nucleic acid epitype probes where X refers to the total number of sites in the nucleic acid template 305 that correspond to CpG sites of the nucleic acid epitype. In the example shown in FIG. 3A, there may be two total sites in the nucleic acid template 305 corresponding to CpG sites of the nucleic acid epitype. In other embodiments, there may be fewer or additional sites in the nucleic acid template 305 corresponding to CpG sites of the nucleic acid epitype. For example, example CGIs described herein in Tables 1-4 may have more than two CpG sites. In the example shown in FIG.3A, the total number of sites X in the nucleic acid template 305 corresponding to CpG sites of the nucleic acid epitype is 2, and therefore, a total of 4 nucleic acid epitype probes (e.g., 310A, 310B, 310C, 310D) are provided. [0075] Specifically, nucleic acid epitype probe 310A can be designed to hybridize with a complementary template sequence in which both site 302A and 302B correspond to methylated CpG sites. As methylated cytosines will remain unaffected by the conversion process and will remain cytosine nucleobases, then the nucleic acid epitype probe 310A will include a first guanine nucleobase at a position corresponding to site 302A and a second guanine nucleobase at a position corresponding to site 302B. Nucleic acid epitype probe 310B can be designed to hybridize with a complementary template sequence in which site 302A corresponds to a methylated CpG site and site 302B corresponds to an unmethylated CpG site. Thus, the nucleic acid epitype probe 310B will include a guanine nucleobase at a position corresponding to site 302A and an adenine nucleobase at a position corresponding to site 302B. Nucleic acid epitype probe 310C can be designed to hybridize with a complementary template sequence in which site 302A corresponds to an unmethylated CpG site and site 302B corresponds to a methylated CpG site. Thus, the nucleic acid epitype probe 310C will include an adenine nucleobase at a position corresponding to site 302A and a guanine nucleobase at a position corresponding to site 302B. Nucleic acid epitype probe 310D can be designed to hybridize with a complementary template sequence in which both sites 302A and 302B correspond to unmethylated CpG sites. Thus, the nucleic acid epitype probe 310D will include a first adenine nucleobase at a position corresponding to site 302A and a second adenine nucleobase at a position corresponding to site 302B. [0076] As further shown in FIG. 3A, the nucleic acid epitype probes 310 are provided to contact the nucleic acid template 305 in the presence of a hybridization solution 320. In particular embodiments, the hybridization solution 320 comprises tetramethylammonium chloride (TMAC). [0077] FIG.3B depicts example hybridization of a nucleic acid epitype probe 310A to a nucleic acid template, in accordance with an embodiment. In this example, nucleic acid epitype probe 310A is fully complementary to a sequence of the nucleic acid template 305. Given that nucleic acid epitype probe 310A was designed to hybridize with a complementary template sequence in which both site 302A and 302B correspond to methylated CpG sites, this indicates that the nucleic acid epitype is fully methylated (e.g., both CpG sites are methylated). Here, although the sequences of the other nucleic acid epitype probes 310B, 310C, and 310D may only differ from the sequence of the nucleic acid epitype probe 310A by a limited number of nucleotides (e.g., 1 or 2 nucleotides at most), nucleic acid epitype probe 310A is able to successfully hybridize with the sequence of the nucleic acid template 305. [0078] Reference is now made to FIGs. 4A, 4B, and 4C, each of which depicts example nucleic acid epitype probes, in accordance with different embodiment. Although FIGs.4A, 4B, and 4C is described in reference to a single nucleic acid epitype probe (e.g., 310A), the description is equally relevant to additional nucleic acid epitype probes (e.g., 310B, 310C, 310D as shown in FIGs. 3A and 3B). [0079] In the embodiment shown in FIG. 4A, the nucleic acid epitype probe 310A may include a sequence 415A that is designed to hybridize with a complementary template sequence. For example, as described above in reference to FIG. 3B, the nucleic acid epitype probe 310A includes a sequence 415A with a first guanine nucleobase at a position corresponding to site 302A and a second guanine nucleobase at a position corresponding to site 302B of the nucleic acid template 305. As shown in FIG.4A, the nucleic acid epitype probe 310A may further include a barcode sequence 410A. Inclusion of a barcode sequence on nucleic acid epitype probes can enable subsequent demultiplexing. In various embodiments, the length of the barcode sequence is between 3 and 20 nucleotides. In various embodiments, the length of the barcode sequence is between 4 and 17 nucleotides, between 5 and 14 nucleotides, between 6 and 11 nucleotides, or between 7 and 8 nucleotides, inclusive. In various embodiments, the length of the barcode sequence is 8 nucleotides. [0080] FIG.4B shows a second embodiment of the nucleic acid epitype probe 310A including a sequence 415A and a detection moiety 420A. In various embodiments, the detection moiety 420A is a fluorescent tag that enables detection of the nucleic acid epitype probe 310A. For example, if performing PCR (e.g., real-time PCR), accumulation of amplicons comprising a sequence of the nucleic acid epitype probe 310A or hybridized to a sequence of the nucleic acid epitype probe 310A will result in detection of signal deriving from fluorescent tag 420A. In various embodiments, the detection moiety 420A may uniquely distinguish the nucleic acid epitype probe 310A from other nucleic acid epitype probes (e.g., the other nucleic acid epitype probes may have other distinguishable detection moieties). [0081] FIG.4C shows a third embodiment of the nucleic acid epitype probe 310A including a sequence 415A and a binding moiety 425A. Here, the binding moiety 425A can enable the nucleic acid epitype probe 310A to couple or bind to a solid support. As described in further detail herein, the binding of the nucleic acid epitype probe 310A to a corresponding solid support can be useful for isolating and enriching the nucleic acid epitype probe 310A. In various embodiments, the binding moiety 425A comprises a biotin moiety. Thus, the biotin moiety can bind to a corresponding streptavidin moiety, e.g., on the solid support. [0082] Although FIGs.4A-4C show three different embodiments in which the nucleic acid epitype probe 310A includes one of a barcode 410A, detection moiety 420A, and binding moiety 425A, in various embodiments, the nucleic acid epitype probe 310A can include combinations of the barcode 410A, detection moiety 420A, and binding moiety 425A. For example, the nucleic acid epitype probe 310A can include a barcode 410A and a detection moiety 420A, but need not include a binding moiety 425A. As another example, the nucleic acid epitype probe 310A can include a barcode 410A and binding moiety 425A, but need not include a detection moiety 420A. As yet another example, the nucleic acid epitype probe 310A can include a detection moiety 420A and binding moiety 425A, but need not include a barcode 410A. In various embodiments, the nucleic acid epitype probe 310A includes each of a barcode 410A, detection moiety 420A, and binding moiety 425A. Example processing and detecting of nucleic acid epitype probe hybridized to nucleic acid template [0083] As discussed herein, step 130 in FIG.1 involves processing a nucleic acid template hybridized to a nucleic acid epitype probe. Reference will be made to FIGs.5A-5C which depict a first embodiment of processing a nucleic acid template hybridized to a nucleic acid epitype probe. Reference will additionally be made to FIG.6, which depicts a second embodiment of processing a nucleic acid template hybridized to a nucleic acid epitype probe. [0084] In various embodiments, processing a nucleic acid template hybridized to a nucleic acid epitype probe involves one or more of isolating the nucleic acid template hybridized to the nucleic acid epitype probe, enriching for the nucleic acid template hybridized to the nucleic acid epitype probe, and dissociating the nucleic acid epitype probe from the nucleic acid template. In various embodiments, processing a nucleic acid template hybridized to a nucleic acid epitype probe involves each of isolating the nucleic acid template hybridized to the nucleic acid epitype probe, enriching for the nucleic acid template hybridized to the nucleic acid epitype probe, and dissociating the nucleic acid epitype probe from the nucleic acid template. [0085] In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises exposing a binding moiety to the solid support. Examples of solid supports include solid beads, a slide (e.g., a glass slide), or a plate (e.g., plate comprising wells). In particular embodiments, the solid support is a solid bead (e.g., a polystyrene solid bead). In various embodiments, the binding moiety may be a moiety located on the nucleic acid template, and therefore, the nucleic acid template is bound to the solid support via the binding moiety. As another example, the binding moiety may be a moiety located on the nucleic acid epitype probe, and therefore, the nucleic acid epitype probe is bound to the solid support via the binding moiety. In various embodiments, the binding moiety is a biotin moiety. Thus, the biotin moiety can bind to a corresponding streptavidin moiety located on the solid support. [0086] In various embodiments, isolating the nucleic acid nucleic acid template hybridized to the nucleic acid epitype probe comprises separating the nucleic acid template hybridized to the nucleic acid epitype probe bound to the solid support from non-specifically associated nucleic acids. In various embodiments, the separation can involve manually separating or removing the solid support bound to the nucleic acid template or nucleic acid epitype probe. In various embodiments, isolating the nucleic acid template hybridized to the nucleic acid epitype probe comprises performing a centrifugation or filtration. [0087] In various embodiments, enriching for the nucleic acid template hybridized to the nucleic acid epitype probe comprises performing one or more washes to remove non-specifically associated nucleic acids. For example, the nucleic acid template hybridized to the nucleic acid epitype probe bound to the solid support can undergo one or more washes (e.g., buffer wash) to remove other unbound nucleic acids (e.g., other nucleic acid epitype probes). In various embodiments, enriching for the nucleic acid template hybridized to the nucleic acid epitype probe comprises performing a centrifugation or filtration to remove other unbound nucleic acids (e.g., other nucleic acid epitype probes). [0088] FIG.5A depicts enrichment of the nucleic acid epitype probe hybridized to the nucleic acid template, in accordance with an embodiment. FIG.5A is an exemplary illustration of a pull-down process for isolating and enriching the nucleic acid template 305 hybridized to a nucleic acid epitype probe 310A. FIG.5A further introduces a solid support 502 and a binding moiety 504. Here, the binding moiety 504 may be a biotin moiety linked to the nucleic acid template 305. Thus, the binding moiety 504 may bind to the solid support 502 via a streptavidin moiety. At this stage, the composition including the solid support 502, binding moiety 504, nucleic acid template 305, and nucleic acid epitype probe 310A can undergo enrichment via one or more washes, centrifugation, or filtration. This removes other additional nucleic acid epitype probes (e.g., 310B, 310C, and 310D) that are not bound to the solid support 502. [0089] Following isolation and enrichment, FIG.5B depicts an example dissociation of the nucleic acid epitype probe from the nucleic acid template, in accordance with an embodiment. In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to an elevated temperature. In various embodiments, the elevated temperature is above 40 ^o C, above 41 ^o C, above 42 ^o C, above 43 ^o C, above 44 ^o C, above 45 ^o C, above 46 ^o C, above 47 ^o C, above 48 ^o C, above 49 ^o C, above 50 ^o C, above 51 ^o C, above 52 ^o C, above 53 ^o C, above 54 ^o C, above 55 ^o C, above 56 ^o C, above 57 ^o C, above 58 ^o C, above 59 ^o C, above 60 ^o C, above 61 ^o C, above 62 ^o C, above 63 ^o C, above 64 ^o C, above 65 ^o C, above 66 ^o C, above 67 ^o C, above 68 ^o C, above 69 ^o C, above 70 ^o C, above 71 ^o C, above 72 ^o C, above 73 ^o C, above 74 ^o C, above 75 ^o C, above 76 ^o C, above 77 ^o C, above 78 ^o C, above 79 ^o C, above 80 ^o C, above 81 ^o C, above 82 ^o C, above 83 ^o C, above 84 ^o C, above 85 ^o C, above 86 ^o C, above 87 ^o C, above 88 ^o C, above 89 ^o C, above 90 ^o C, above 91 ^o C, above 92 ^o C, above 93 ^o C, above 94 ^o C, above 95 ^o C, above 96 ^o C, above 97 ^o C, above 98 ^o C, above 99 ^o C, or above 100 ^o C. In various embodiments, the elevated temperature is between 40 ^o C and 100 ^o C. In various embodiments, the elevated temperature is between 45 ^o C and 95 ^o C, between 50 ^o C and 90 ^o C, between 55 ^o C and 90 ^o C, between 60 ^o C and 85 ^o C, between 65 ^o C and 80 ^o C, between 70 ^o C and 75 ^o C, between 45 ^o C and 75 ^o C, between 50 ^o C and 70 ^o C, between 55 ^o C and 65 ^o C, or between 58 ^o C and 62 ^o C. [0090] In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to an elevated pH. In various embodiments, the elevated pH is above 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, or 13.9. In various embodiments, the elevated pH is between 7.0 and 13.0, between 7.5 and 12.5, between 8.0 and 12.0, between 8.5 and 11.5, between 9.0 and 11.0, between 9.5 and 10.5, between 9.8 and 10.2, between 7.0 and 10.0, between 7.5 and 9.5, between 8.0 and 9.0, between 10.0 and 13.0, between 10.5 and 12.5, between 11.0 and 12.0, or between 11.3 and 11.7. [0091] In various embodiments, dissociating the nucleic acid epitype probe from the nucleic acid template comprises exposing the nucleic acid epitype probe and nucleic acid template to a combination of an elevated temperature and elevated pH. In various embodiments, the combined elevated temperature and elevated pH is at least 50 ^o C and at least pH = 8.0. In various embodiments, the combined elevated temperature and elevated pH is at least 60 ^o C and at least pH = 9.0. In various embodiments, the combined elevated temperature and elevated pH is at least 60 ^o C and at least pH = 10.0. [0092] After the nucleic acid epitype probe is dissociated, FIG.5C depicts subsequent processing of the nucleic acid epitype probe 310A, including amplification and sequencing of the nucleic acid epitype probe, in accordance with an embodiment. The amplification 510 step includes providing amplification primers and reagents to amplify the nucleic acid epitype probe 310A. In various embodiments, amplification primers and reagents can be selectively provided to amplify the nucleic acid epitype probe 310A. For example, in various embodiments, the nucleic acid epitype probe 310A may include a detection moiety (e.g., such as detection moiety 420A described in FIG.4B). The detection moiety may uniquely distinguish the nucleic acid epitype probe 310A from other nucleic acid epitype probes. Thus, by detecting the detection moiety, the identity of the nucleic acid epitype probe 310A can be identified, and appropriate amplification primers (e.g., primers specific for sequences of the nucleic acid epitype probe 310A) can be provided for amplification. [0093] In various embodiments, nucleic acid epitype probe 310A shown in FIG.5C can be pooled with other nucleic acid epitype probes. In various embodiments, the other nucleic acid epitype probes may have been dissociated from other nucleic acid templates that underwent the same processing as nucleic acid template 305 shown in FIGs.3A and 3B. For example, each of the other nucleic acid templates may have been exposed to 2 ^௫ different nucleic acid epitype probes that were designed to interrogate the full range of possible CpG methylation statuses of the nucleic acid epitype of the other nucleic acid template. Thus, each of the other nucleic acid epitype probes that are pooled with nucleic acid epitype probe 310A may have previously hybridized with another nucleic acid template. By pooling the nucleic acid epitype probes, this enables bulk amplification 510 and bulk sequencing 520 of large numbers of nucleic acid epitype probes that were, at one point, hybridized with a corresponding nucleic acid template. Thus, high throughput screening of various samples can be performed simultaneously through bulk amplification 510 and sequencing 520. [0094] After amplification 510, the amplicons are sequenced. Specifically, sequencing 520 involves sequencing the nucleic acid epitype probe (e.g., nucleic acid epitype probe 310A) to determine the identity of the nucleic acid epitype. For example, returning to the prior example, nucleic acid epitype probe 310A may include a first guanine nucleobase at a first position corresponding to a first CpG site of the nucleic acid epitype, and a second guanine nucleobase at a second position corresponding to a second CpG site nucleic acid epitype. Thus, by sequencing the nucleic acid epitype probe 310A, the nucleic acid epitype can be determined to have a cytosine at a first position corresponding to the first CpG site and a cytosine at a second position corresponding to the second CpG site. These two cytosines were likely methylated in the original cfDNA, because they underwent conversion (e.g., bisulfite conversion) and remained unaffected. Thus, by sequencing the nucleic acid epitype probe 310A, the nucleic acid epitype can be determined to have included a first methylated cytosine at a first CpG site and a second methylated cytosine at a second CpG site. Here, the nucleic acid epitype may be deemed fully methylated (e.g., since all CpG sites were methylated) as opposed to being partially methylated or non-methylated. Further details of sequencing, such as performance of next generation sequencing, are described herein. [0095] In various embodiments, after sequencing 520 nucleic acid epitypes in bulk, the method may involve demultiplexing sequencing data from the nucleic acid epitype probe and other nucleic acid epitype probes. In various embodiments, demultiplexing the sequencing data can be performed using differing barcodes (e.g., barcode 410A described in FIG. 4A) of the nucleic acid epitype probe and barcodes of the additional nucleic acid epitype probes. [0096] Reference is now made to FIG.6, which shows an example process for amplifying and detecting a nucleic acid epitype, in accordance with another embodiment. FIG. 6 introduces the nucleic acid template 305 hybridized to a nucleic acid epitype probe 310A, as was shown following FIG. 3B. FIG. 6 further shows an embodiment in which the nucleic acid epitype probe 310A includes a detection moiety 420A. In such embodiments, processing a nucleic acid template hybridized to a nucleic acid epitype probe involves amplifying the nucleic acid template. Here, the nucleic acid epitype probe 310A hybridized to the nucleic acid template 305 serves as a primer, such as an amplification primer, for amplifying the nucleic acid template 305. In various embodiments, amplification of the nucleic acid template involves performing polymerase chain reaction (PCR). Example PCR assays include, but are not limited to real-time PCR assays, quantitative real-time PCR (qPCR) assays, digital PCR (dPCR), allele-specific PCR assays, reverse-transcription PCR assays and reporter assays. [0097] As shown in FIG.6, Z cycles of nucleic acid amplification can be performed. In various embodiments, Z is between 20 and 80 cycles. In various embodiments, Z is between 25 and 70 cycles or between 30 and 60 cycles. In various embodiments, Z is between 30 and 50 cycles. In various embodiments, Z cycles of nucleic acid amplification is calculated according to when a signal from the detection moiety 420A is detected. For example, as shown in FIG. 6, at step 610, Z can refer to the number of amplification cycles until detection of a signal from the detection moiety 420A. The number of amplification cycles until detection of the signal is hereafter referred to as the cycle threshold (Ct) value. Here, detection of the signal from the detection moiety 420A can be indicative of presence of an amplification product, such as presence of an amplicon derived from the nucleic acid template. [0098] Step 615 involves detecting the nucleic acid epitype. In various embodiments, detecting the nucleic acid epitype involves correlating the detected signal in step 610 to a sequence of a nucleic acid epitype probe and/or a sequence of a nucleic acid template. For example, according to the embodiment shown in FIG.6, the signal may be derived from the detection moiety 420A that is associated with the nucleic acid epitype probe 310A. Generally, signals from different detection moieties may be sufficiently unique to distinguish each detection moiety. Thus, detecting the signal derived from detection moiety 420A indicates the presence of amplicons comprising a sequence of the nucleic acid epitype probe 310A. [0099] In various embodiments, step 615 involves determining a methylation status of the nucleic acid epitype. The methylation status of the nucleic acid epitype is one of non- methylated, partially methylated, or fully methylated. As an example, nucleic acid epitype probe 310A associated with detection moiety 420A may include a first guanine nucleobase at a first position corresponding to a first CpG site of the nucleic acid epitype, and a second guanine nucleobase at a second position corresponding to a second CpG site nucleic acid epitype. Thus, detecting a signal from the detection moiety 420A indicates the presence of amplicons comprising a sequence of nucleic acid epitype 310A, and the nucleic acid epitype can be determined to have a cytosine at a first position corresponding to the first CpG site and a cytosine at a second position corresponding to the second CpG site. These two cytosines were likely methylated in the original cfDNA, because they underwent conversion (e.g., bisulfite conversion) and remained unaffected. Thus, by detecting a signal from a detection moiety associated with nucleic acid epitype probe 310A, the nucleic acid epitype can be determined to have included a first methylated cytosine at a first CpG site and a second methylated cytosine at a second CpG site. Here, the nucleic acid epitype may be deemed fully methylated (e.g., since all CpG sites were methylated) as opposed to being partially methylated or non-methylated. [00100] Step 620 involves comparing the Z number of amplification cycles (Ct value) to a corresponding Ct value for a control sample. In various embodiments, the control sample is a negative control sample (e.g., a sample obtained from a subject known to not have a health condition). In various embodiments, the control sample is a positive control sample (e.g., a sample obtained from a subject known to have a health condition). In various embodiments, step 620 involves comparing the Z number of amplification cycles (Ct value) to a corresponding Ct value for a negative control sample and further comparing to a corresponding Ct value for a positive control sample. Thus, the difference in Ct values (e.g., delta-Ct value) between negative control and the target sample, as well as between the positive control and the sample, can be informative for determining presence of absence of the health condition in the target sample. Health Conditions [00101] The disclosure provides methods for detecting a nucleic acid epitype, which can be useful for screening one or more subjects for a presence or absence of a health condition. In various embodiments, after detecting a nucleic acid epitype, a more complex diagnostic tool can be implemented to confirm the detected nucleic acid epitype. In various embodiments, the patient may be suspected of having a health condition, but may not have been previously diagnosed with a health disorder. In various embodiments, the patient is healthy and is not yet suspected of having a health condition. [00102] In various embodiments, the health condition can be a disease or disorder. Examples of diseases and/or disorders can include, for example, a cancer, inflammatory disease, neurodegenerative disease, autoimmune disorder, neuromuscular disease, metabolic disorder (e.g., diabetes), cardiac disease, or fibrotic disease (e.g., idiopathic pulmonary fibrosis). [00103] In particular embodiments, the health condition is a cancer. In various embodiments, the cancer is an early stage cancer. In various embodiments, the cancer is a preclinical phase cancer. In various embodiments, the cancer is a stage I cancer. In various embodiments, the cancer is a stage II cancer. Thus, the methods disclosed herein enable the screening and diagnosis of an individual for an early stage or preclinical stage cancer. [00104] In various embodiments, the cancer is any of an acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, soft tissue sarcoma, lymphoma, anal cancer, gastrointestinal cancer, brain cancer, skin cancer, bile duct cancer, bladder cancer, bone cancer, breast cancer, lung cancer, cardiac cancer, central nervous system cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative neoplasms, colorectal cancer, uterine cancer, esophageal cancer, head and neck cancer, eye cancer, fallopian tube cancer, gallbladder cancer, gastric cancer, germ cell tumor, gestational trophoblastic cancer, hairy cell leukemia, liver cancer, Hodgkin lymphoma, intraocular melanoma, pancreatic cancer, kidney cancer, leukemia, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma neoplasms, myelodysplastic neoplasms, ovarian cancer, parathyroid cancer, penile cancer, pheochromocytoma, pituitary cancer, plasma cell neoplasm, primary peritoneal cancer, prostate cancer, rectal cancer, retinoblastoma, sarcoma, small intestine cancer, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer. [00105] In various embodiments, the inflammatory disease can be any one of acute respiratory distress syndrome (ARDS), acute lung injury (ALI), alcoholic liver disease, allergic inflammation of the skin, lungs, and gastrointestinal tract, allergic rhinitis, ankylosing spondylitis, asthma (allergic and non-allergic), atopic dermatitis (also known as atopic eczema), atherosclerosis, celiac disease, chronic obstructive pulmonary disease (COPD), chronic respiratory distress syndrome (CRDS), colitis, dermatitis, diabetes, eczema, endocarditis, fatty liver disease, fibrosis (e.g., idiopathic pulmonary fibrosis, scleroderma, kidney fibrosis, and scarring), food allergies (e.g., allergies to peanuts, eggs, dairy, shellfish, tree nuts, etc.), gastritis, gout, hepatic steatosis, hepatitis, inflammation of body organs including joint inflammation including joints in the knees, limbs or hands, inflammatory bowel disease (IBD) (including Crohn's disease or ulcerative colitis), intestinal hyperplasia, irritable bowel syndrome, juvenile rheumatoid arthritis, liver disease, metabolic syndrome, multiple sclerosis, myasthenia gravis, neurogenic lung edema, nephritis (e.g., glomerular nephritis), non-alcoholic fatty liver disease (NAFLD) (including non-alcoholic steatosis and non-alcoholic steatohepatitis (NASH)), obesity, prostatitis, psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), sarcoidosis sinusitis, splenitis, seasonal allergies, sepsis, systemic lupus erythematosus, uveitis, and UV-induced skin inflammation. [00106] In various embodiments, the neurodegenerative disease can be any one of Alzheimer's disease, Parkinson's disease, traumatic CNS injury, Down Syndrome (DS), glaucoma, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington’s disease. [00107] Exemplary metabolic disorders include, for example, diabetes, insulin resistance, lysosomal storage disorders (e.g., Gaucher’s disease, Krabbe disease, Niemann Pick disease types A and B, multiple sclerosis, Fabry’s disease, Tay Sachs disease, and Sandhoff Variant A, B), obesity, cardiovascular disease, and dyslipidemia. Sequencing and Read Alignment [00108] Disclosed herein are methods for sequencing nucleic acid epitype probes e.g., to determine the identity of a nucleic acid epitype. Sequencing can be performed using commercially available next generation sequencing (NGS) platforms, including platforms that perform any of sequencing by synthesis, sequencing by ligation, nanopore sequencing, pyrosequencing, using reversible terminator chemistry, using phospholinked fluorescent nucleotides, or real-time sequencing. As an example, amplicons (e.g., amplicons comprising a sequence of a nucleic acid epitype probe) may be sequenced on an Illumina MiSeq platform. [00109] Nanopore sequencing refers to real-time sequencing of nucleic acids by detecting changes in electrical current as nucleic acids pass through a protein nanopore. Here, nucleic acids need not undergo amplification (e.g., PCR amplification) or labeling. Depending on the various factors of the nucleotide base that causes the electrical change, such as geometry, size, and chemical composition, nanopore sequencing enables real-time readout of nucleotide bases that make up a nucleic acid. Additional details for nanopore sequencing are found in US Patent No.10,480,027, which is incorporated by reference in its entirety. [00110] On the Solexa / Illumina platform, sequencing data is produced in the form of short readings. In this method, fragments of a library of NGS fragments are captured on the surface of a flow cell that is coated with oligonucleotide anchor molecules. An anchor molecule is used as a PCR primer, but due to the length of the matrix and its proximity to other nearby anchor oligonucleotides, elongation by PCR leads to the formation of a “vault” of the molecule with its hybridization with the neighboring anchor oligonucleotide and the formation of a bridging structure on the surface of the flow cell. These DNA loops are denatured and cleaved. Straight chains are then sequenced using reversibly stained terminators. The nucleotides included in the sequence are determined by detecting fluorescence after inclusion, where each fluorescent and blocking agent is removed prior to the next dNTP addition cycle. Additional details for sequencing using the Illumina platform are found in Voelkerding et al., Clinical Chem., 55: 641- 658, 2009; MacLean et al., Nature Rev. Microbiol., 7: 287-296; US Patent No. 6,833,246; US Patent No.7,115,400; US Patent No.6,969,488; each of which is hereby incorporated by reference in its entirety. [00111] Sequencing of nucleic acid molecules using SOLiD technology includes clonal amplification of the library of NGS fragments using emulsion PCR. After that, the granules containing the matrix are immobilized on the derivatized surface of the glass flow cell and annealed with a primer complementary to the adapter oligonucleotide. However, instead of using the indicated primer for 3 'extension, it is used to obtain a 5' phosphate group for ligation for test probes containing two probe-specific bases followed by 6 degenerate bases and one of four fluorescent labels. In the SOLiD system, test probes have 16 possible combinations of two bases at the 3 'end of each probe and one of four fluorescent dyes at the 5' end. The color of the fluorescent dye and, thus, the identity of each probe, corresponds to a certain color space coding scheme. After many cycles of alignment of the probe, ligation of the probe and detection of a fluorescent signal, denaturation followed by a second sequencing cycle using a primer that is shifted by one base compared to the original primer. In this way, the sequence of the matrix can be reconstructed by calculation; matrix bases are checked twice, which leads to increased accuracy. Additional details for sequencing using SOLiD technology are found in Voelkerding et al., Clinical Chem., 55: 641-658, 2009; MacLean et al., Nature Rev. Microbiol., 7: 287-296; US Patent No.5,912,148; US Patent No.6,130,073; each of which is incorporated by reference in its entirety. [00112] In particular embodiments, HeliScope from Helicos BioSciences is used. Sequencing is achieved by the addition of polymerase and serial additions of fluorescently-labeled dNTP reagents. Switching on leads to the appearance of a fluorescent signal corresponding to dNTP, and the specified signal is captured by the CCD camera before each dNTP addition cycle. The reading length of the sequence varies from 25-50 nucleotides with a total yield exceeding 1 billion nucleotide pairs per analytical work cycle. Additional details for performing sequencing using HeliScope are found in Voelkerding et al., Clinical Chem., 55: 641-658, 2009; MacLean et al., Nature Rev. Microbiol., 7: 287-296; US Patent No.7,169,560; US Patent No.7,282,337; US Patent No.7,482,120; US Patent No.7,501,245; US Patent No.6,818,395; US Patent No. 6,911,345; US Patent No.7,501,245; each of which is incorporated by reference in its entirety. [00113] In some embodiments, a Roche sequencing system 454 is used. Sequencing 454 involves two steps. In the first step, DNA is cut into fragments of approximately 300-800 base pairs, and these fragments have blunt ends. Oligonucleotide adapters are then ligated to the ends of the fragments. The adapter serves as primers for amplification and sequencing of fragments. Fragments can be attached to DNA-capture beads, for example, streptavidin-coated beads, using, for example, an adapter that contains a 5'-biotin tag. Fragments attached to the granules are amplified by PCR within the droplets of an oil-water emulsion. The result is multiple copies of cloned amplified DNA fragments on each bead. At the second stage, the granules are captured in wells (several picoliters in volume). Pyrosequencing is carried out on each DNA fragment in parallel. Adding one or more nucleotides leads to the generation of a light signal, which is recorded on the CCD camera of the sequencing instrument. The signal intensity is proportional to the number of nucleotides included. Pyrosequencing uses pyrophosphate (PPi), which is released upon the addition of a nucleotide. PPi is converted to ATP using ATP sulfurylase in the presence of adenosine 5 'phosphosulfate. Luciferase uses ATP to convert luciferin to oxyluciferin, and as a result of this reaction, light is generated that is detected and analyzed. Additional details for performing sequencing 454 are found in Margulies et al. (2005) Nature 437: 376-380, which is hereby incorporated by reference in its entirety. [00114] Ion Torrent technology is a DNA sequencing method based on the detection of hydrogen ions that are released during DNA polymerization. The microwell contains a fragment of a library of NGS fragments to be sequenced. Under the microwell layer is the hypersensitive ion sensor ISFET. All layers are contained within a semiconductor CMOS chip, similar to the chip used in the electronics industry. When dNTP is incorporated into a growing complementary chain, a hydrogen ion is released that excites a hypersensitive ion sensor. If homopolymer repeats are present in the sequence of the template, multiple dNTP molecules will be included in one cycle. This results in a corresponding amount of hydrogen atoms being released and in proportion to a higher electrical signal. This technology is different from other sequencing technologies that do not use modified nucleotides or optical devices. Additional details for Ion Torrent Technology is found in Science 327 (5970): 1190 (2010); US Patent Application Publication Nos.20090026082, 20090127589, 20100301398, 20100197507, 20100188073, and 20100137143, each of which is incorporated by reference in its entirety. [00115] In various embodiments, sequencing reads obtained from the NGS methods can be filtered by quality and grouped by barcode sequence e.g., to enable demultiplexing of sequences from different samples. In some embodiments, a given sequencing read may be discarded if more than about 20% of its bases have a quality score (Q-score) less than Q20, indicating a base call accuracy of about 99%. In some embodiments, a given sequencing read may be discarded if more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30% have a Q-score less than Q10, Q20, Q30, Q40, Q50, Q60, or more, indicating a base call accuracy of about 90%, about 99%, about 99.9%, about 99.99%, about 99.999%, about 99.9999%, or more, respectively. [00116] In some embodiments, sequencing reads associated with a barcode containing less than 50 reads may be discarded to ensure that all barcode groups, representing individual samples, contain a sufficient number of high-quality reads. In some embodiments, all sequencing reads associated with a barcode containing less than 30, less than 40, less than 50, less than 60, less than 70, less than 80, less than 90, less than 100 or more may be discarded to ensure the quality of the barcode groups representing individual samples. [00117] In various embodiments, sequence reads with common barcode sequences (e.g., meaning that sequence reads originated from the same sample) may be aligned to a reference genome using known methods in the art to determine alignment position information. For example, sequence reads can be aligned to a range of positions of a reference genome. The alignment position information may indicate a beginning position and an end position of a region in the reference genome that corresponds to a beginning nucleotide base and end nucleotide base of a given sequence read. In various embodiments, a region in the reference genome may be associated with a particular genomic region, such as a CGI shown in any of Tables 1-4. Example Kit Embodiments [00118] Also disclosed herein are kits for performing the methods disclosed herein (e.g., for detecting a nucleic acid epitype and/or for detecting circulating tumor DNA in a biological sample of a subject). Such kits can include reagents for performing the methods disclosed herein, such as reagents for converting nucleic acids (e.g., via bisulfite conversion) from obtained samples and/or reagents comprising nucleic acid epitype probes. In particular embodiments, a kit includes reagents comprising one or more nucleic acid epitype probes designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated. [00119] In various embodiments, a kit includes reagents comprising a plurality of nucleic acid epitype probes that are sufficient for interrogating a full range of possible CpG methylation ^{statuses of a nucleic acid epitype. For example, a kit may include reagents comprising} _{2௫ nucleic acid epitype probes, where X refers to the total number of CpG sites of the nucleic} acid epitype. [00120] In various embodiments, a kit can include instructions for use of a set of reagents. For example, a kit can include instructions for converting nucleic acids from an obtained sample e.g., by performing bisulfite conversion. In various embodiments, a kit can include instructions for providing a nucleic acid epitype probe designed to be complementary to a converted nucleic acid epitype, wherein the converted nucleic acid epitype comprises one or more CpG sites that, prior to conversion, were non-methylated, partially methylated, or fully methylated. In various embodiments, a kit can include instructions for contacting a nucleic acid template derived from converted cell-free DNA obtained from a biological sample of a subject with the nucleic acid epitype probe, wherein the epitype probe hybridizes to the nucleic acid template if the epitype probe is complementary to the nucleic acid template. In various embodiments, a kit can include instructions for detecting the nucleic acid epitype by detecting the nucleic acid epitype probe that hybridized to the nucleic acid template. [00121] In various embodiments, the instructions of the kit can be present in a variety of forms, one or more of which can be present in the kit. One form in which these instructions can be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc. Yet another means would be a computer readable medium, e.g., diskette, CD, hard-drive, network data storage, etc., on which the information has been recorded. Yet another means that can be present is a website address which can be used via the internet to access the information at a removed site. Any convenient means can be present in the kits. EXAMPLES [00122] Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., percentages, etc.), but some experimental error and deviation should be allowed for. Example 1: Example Library Preparation Prepare target specimen [00123] The target specimen type (e.g., DNA, RNA) is isolated from a patient’s biological source (e.g., tissue, blood, plasma, serum, saliva, feces, etc.). That specimen can be isolated by a contract research organization, private or service laboratory or hospital, or isolated using an internal procedure. All target specimens are assayed for quality and quantity measurements. Convert Unmethylated Cytosines to Uracils [00124] Bisulfite conversion is performed on DNA by denaturation using high heat, preferential deamination (at an acidic pH) of unmethylated cytosines, which are then converted to uracil by desulfonation (at an alkaline pH). Methylated cytosines remain unchanged on the single- VWUDQGHG^'1$^^VV'1$^^SURGXFW^ௗௗ Generate library [00125] The bisulfite converted ssDNA undergoes Adaptase® technology from Swift Biosciences, which is an enzymatic reaction resulting in unbiased addition of a truncated adapter. The Adaptase® enzymatic reaction performs end-repairing, tailing of 3’ ends and ligation of first truncated adapter complement to 3’ ends simultaneously. A uracil-free reverse complement to the bisulfite converted ssDNA is then generated using the truncated adapter to prime and extend. A solid-phase reversible immobilization (SPRI) selection is performed to remove unwanted ssDNA fragments, excess adapters and molecules. A ligation reaction is performed, adding truncated P5 adapter to the 3’ end of the uracil-free reverse complement fragment. A solid-phase reversible immobilization (SPRI) selection is performed to remove unwanted ssDNA fragments, excess adapters and molecules. Indexing PCR amplification is performed with a high fidelity DNA polymerase and unique, known 8-bp barcodes. Indices allow for sample multiplex for the downstream assay. The product is a bisulfite converted dsDNA library with full length adapters. Post-PCR, a SPRI selection is done to remove unwanted ssDNA fragments, excess primers, excess adapters and excess molecules. After library construction, the library quality and quantity are evaluated using the Agilent TapeStation and Qubit™ Fluorometer, respectively. Example 2: Example Epitype screening by Allele-specific Real-Time PCR [00126] Constructed libraries, as described in Example 1, undergo quality control checks. Libraries that pass all quality control checks move forward to epitype screening. Allele-specific real-time PCR is performed by combining library DNA with PCR reagents and primers specific for target epitype sequences ¹ . The primers (e.g., nucleic acid epitype probes) are designed to have single-base discrimination between tumor and non-tumor sequences. Methods involve performing real-time PCR (or digital PCR) for 30-50 cycles and monitoring the output for signal via fluorescence from amplified target DNA or probe sequence. Cycle threshold values (Ct) are recorded and exported for analysis. The delta-Ct between negative control, positive control, and sample are calculated to determine presence or absence of target tumor sequences. Slight modifications of this protocol allows for end-point PCR detection of RNA or DNA of tumor sequences ^2,3,4 . This screening tool is further confirmed by a more complex diagnostic tool. Example 3: Example Epitype screening by Hybridized Probe Sequencing [00127] FIG.7 shows an example process for detecting a nucleic acid epitype. FIG. 7 shows a first step of obtaining bisulfite converted nucleic acids (e.g., bisulfite converted cell free DNA). As described in Example 1, the bisulfite converted cfDNA undergoes library construction to generate a biotinylated library. Constructed libraries undergo quality control checks. Libraries that pass all quality control checks move forward to epitype screening. [00128] Nucleic acids of the library (e.g., nucleic acid templates) are pulled down via a streptavidin probe. Libraries are hybridized to a custom, epitype specific, barcoded, biotinylated probe. Nucleic acid epitype probes are provided in the presence of a hybridization solution including tetramethylammonium chloride (TMAC). Here, presence of TMAC drives complete hybridization ^6,7 , which specifically increases the stability of A:T base pairs to be similar to G:C base pairs, resulting in a stabilized hybridization temperature regardless of probe sequence composition ⁸ . [00129] The library fragment hybridized to the biotinylated probe is pulled down by streptavidin beads, thereby enriching for the target regions of interest. The streptavidin bead-bound library is sequentially washed with buffers to remove non-specifically associated library fragments. Following washes and recovery of captured libraries, samples are enriched for on target fragments and depleted for off-target fragments. The bead-bound epitype target probe then undergoes dissociation from the hybridization to the library fragment DNA through high temperature and high pH conditions. Probes with non-overlapping barcodes are pooled to multiplex for shallow sequencing. Sequencing is completed on an iSeq using paired end 150x150 base sequencing with a 10% PhiX spike-in. Sequencing data generated is then demultiplexed utilizing the assigned barcode, aligned to the human genome and trimmed to enrich for epitype specific data only. This cleaned-up data is then processed through a quality pipeline to collapse duplicate reads and evaluate the sequencing data generated. A report is then generated with the specific epitype probe that was hybridized per library, showing positive enrichment for that specific cancer signal. This screening tool is further confirmed by a more complex diagnostic tool. References 1. Lang et al., 2011. J. Mol. Diag: 13 (1), 23-28. 2. Mitchell et al., 2008. PNAS:105 (30), 10513–10518. 3. Chubarov et al., 2020. Diagnostics: 10, 872-886. 4. Fox et al., 1998. British J. Cancer: 77(8),1267-1274. 5. Corey et al., 1997. Int. J. Cancer:71,1019–1028. 6. Shuber et al., 1997. Hum. Mol Genet: 6(3),337-347. 7. Öhrmlam et al., 2010. Nucleic Acids Research: (38)21,e195. 8. Shuber et al., 1993. Hum. Mol. Genet: 2(2),153-158. 9. Swift Biosciences. Accel-NGS® Methyl-Seq DNA Library Kit Protocol. Cat. No 30024/30096. www.swiftbiosci.com

TABLE^ϭ^^^List^of^CGIs Reference Pos^(hg19^coordinates) 1 chr13:108518334^108518633 2 chr6:137242315^137245442 3 chr2:177016416^177016632 4 chr5:2738953^2741237 5 chr4:111553079^111554210 6 chr15:96909815^96910030 7 chr6:42072032^42072701 8 chr10:123922850^123923542 9 chr16:86612188^86613821 10 chr19:47151768^47153125 11 chr1:110610265^110613303 12 chr5:3594467^3603054 13 chr9:126773246^126780953 14 chr3:138656627^138659107 15 chr4:4859632^4860191 16 chr10:118895963^118898037 17 chr7:103086344^103086840 18 chr19:407011^409511 19 chr10:22764708^22767050 20 chr16:86549069^86550512 21 chr9:96713326^96718186 22 chr8:139508795^139509774 23 chr2:73143055^73148260 24 chr8:26721642^26724566 25 chr9:129386112^129389231 26 chr12:49483601^49484255 27 chr16:54325040^54325703 28 chr8:72468560^72469561 29 chr18:70533965^70536871 30 chr9:98111364^98112362 31 chr1:50882997^50883426 32 chr10:88122924^88127364 33 chr11:31839363^31839813 34 chr10:101290025^101290338 35 chr6:41528266^41528900 36 chr16:51183699^51188763 37 chr5:140346105^140346931 38 chr9:23820691^23822135 39 chr20:690575^691099 40 chr1:177133392^177133846 41 chr5:45695394^45696510 42 chr2:45395869^45398186 43 chr20:48184193^48184833 44 chr6:6002471^6005125 45 chr14:101192851^101193499 chr8:4848968^4852635 chr8:53851701^53854426 chr12:186863^187610 chr5:54519054^54519628 chr6:108485671^108490539 chr3:157815581^157816095 chr11:626728^628037 chr2:177012371^177012675 chr17:59531723^59535254 chr16:55364823^55365483 chr8:99960497^99961438 chr7:42267546^42267823 chr17:14202632^14203258 chr10:102891010^102891794 chr5:174158680^174159729 chr14:33402094^33404079 chr2:177036254^177037213 chr10:106399567^106402812 chr6:166579973^166583423 chr11:123066517^123066986 chr11:44327240^44327932 chr14:95237622^95238211 chr9:102590742^102591303 chr15:76630029^76630970 chr4:24801109^24801902 chr8:97169731^97170432 chr3:6902823^6903516 chr22:48884884^48887043 chr15:45408573^45409528 chr9:100610696^100611517 chr4:174448333^174448845 chr16:20084707^20085305 chr4:174439812^174440249 chr6:10381558^10382354 chr15:35046443^35047480 chr10:119494493^119494991 chr5:72676120^72678421 chr11:44325657^44326517 chr17:46670522^46671458 chr14:92789494^92790712 chr4:174459200^174460054 chr2:80549578^80549798 chr7:153748407^153750444 chr6:1389139^1391393 chr16:49314037^49316543 chr2:105459127^105461770 chr21:38079941^38081833 chr4:174427891^174428192 chr14:60973772^60974123 chr8:99985733^99986983 chr2:63281034^63281347 chr12:101109863^101111622 chr1:119549144^119551320 chr5:38257825^38259136 chr5:54522302^54523533 chr1:165324191^165326328 chr15:33602816^33604003 chr10:118030732^118034230 chr2:45240372^45241579 chr4:174430386^174430861 chr6:50810642^50810994 chr5:122430676^122431443 chr10:109674196^109674964 chr8:97172634^97173880 chr8:11536767^11538961 chr5:180486154^180486892 chr2:38301276^38304518 chr10:1778784^1780018 chr12:54424610^54425173 chr17:46669434^46669811 chr11:8190226^8190671 chr8:25900562^25905842 chr12:81102034^81102716 chr7:27199661^27200960 chr10:119311204^119312104 chr12:130387609^130389139 chr7:155258827^155261403 chr6:117591533^117592279 chr10:111216604^111217083 chr1:29585897^29586598 chr2:144694666^144695180 chr12:48397889^48398731 chr5:2748368^2757024 chr12:114845861^114847650 chr2:80529677^80530846 chr5:1874907^1879032 chr6:100905952^100906686 chr15:96904722^96905050 chr5:134374385^134376751 chr2:66652691^66654218 chr12:54440642^54441543 chr6:108495654^108495986 chr17:70112824^70114271 chr3:87841796^87842563 chr7:96650221^96651551 chr4:110222970^110224257 chr6:78172231^78174088 chr7:155164557^155167854 chr12:113900750^113906442 chr9:112081402^112082905 chr12:114886354^114886579 chr5:3590644^3592000 chr2:119592602^119593845 chr20:21485932^21496714 chr18:11148307^11149936 chr17:46824785^46825372 chr10:100992156^100992687 chr14:36986362^36990576 chr18:55094825^55096310 chr15:96895306^96895729 chr17:36717727^36718593 chr2:223183013^223185468 chr7:30721372^30722445 chr1:53527572^53528974 chr18:56939624^56941540 chr5:175085004^175085756 chr10:50817601^50820356 chr14:60975732^60978180 chr15:89920793^89922768 chr9:122131086^122132214 chr1:217311467^217311773 chr14:38724254^38725537 chr14:61103978^61104663 chr18:73167402^73167920 chr1:50880916^50881516 chr2:241758141^241760783 chr11:31825743^31826967 chr7:27260101^27260467 chr20:41817475^41819212 chr3:238391^240140 chr7:121950249^121950927 chr5:72526203^72526497 chr15:96903311^96903711 chr10:26504383^26507434 chr6:100915602^100915883 chr1:18962842^18963481 chr3:127794369^127796136 chr7:27203915^27206462 chr8:25899335^25899692 chr12:114838312^114838889 chr6:38682949^38683265 chr11:31841315^31842003 chr4:174451828^174452962 chr9:129372737^129378106 chr2:176964062^176965509 chr2:176931575^176932663 chr12:114833911^114834210 chr11:79148358^79152200 chr2:177024501^177025692 chr5:172672311^172672971 chr7:27291119^27292197 chr1:180198119^180204975 chr14:37126786^37128274 chr2:200333687^200334172 chr14:58331676^58333121 chr3:147131066^147131333 chr13:109147798^109149019 chr14:48143433^48145589 chr6:100905444^100905697 chr17:14200579^14200996 chr6:1379693^1380014 chr1:34642382^34643024 chr2:119599059^119599299 chr2:119613031^119615565 chr4:85413997^85414874 chr9:17906419^17907488 chr12:29302034^29302954 chr20:10200088^10200384 chr8:57358126^57359415 chr10:63212495^63213009 chr2:176936246^176936809 chr11:20618197^20619920 chr18:19744936^19752363 chr14:29234889^29235908 chr17:46673532^46674181 chr4:144620822^144622218 chr16:82660651^82661813 chr3:192125821^192127994 chr2:119599458^119600966 chr22:44257942^44258612 chr19:13616752^13617267 chr3:147138916^147139564 chr9:969529^973276 chr18:55103154^55108853 chr4:174422024^174422443 chr4:57521621^57522703 chr15:79724099^79725643 chr14:37135513^37136348 chr10:23480697^23482455 chr2:45169505^45171884 chr18:30349690^30352302 chr6:99291327^99291737 chr9:21970913^21971190 chr4:107146^107898 chr12:117798076^117799448 chr2:219736132^219736592 chr10:118892161^118892639 chr11:27743472^27744564 chr12:65218245^65219143 chr12:75601081^75601752 chr7:54612324^54612558 chr6:100912071^100913337 chr10:102905714^102906693 chr8:87081653^87082046 chr6:50818180^50818431 chr1:91189139^91189400 chr2:118981769^118982466 chr10:50602989^50606783 chr17:59528979^59530266 chr4:147559205^147561901 chr1:4713989^4716555 chr13:102568425^102569495 chr16:6068914^6070401 chr22:29709281^29712013 chr10:100993820^100994188 chr6:391188^393790 chr2:176977284^176977540 chr4:4868440^4869173 chr6:137809342^137810204 chr12:54321301^54321721 chr2:105468851^105473488 chr8:55366180^55367628 chr12:72665683^72667551 chr4:54966163^54968063 chr5:134366913^134367438 chr1:226075150^226075680 chr20:17206528^17206952 chr4:172733734^172735118 chr18:55019707^55021605 chr2:162279835^162280709 chr6:1381743^1385211 chr7:103968783^103969959 chr6:150358872^150359394 chr2:119914126^119916663 chr7:27278945^27279469 chr12:114851957^114852360 chr16:24267040^24267527 chr6:7229877^7230865 chr2:45227644^45228783 chr4:174450046^174451469 chr4:154712073^154712706 chr3:22413492^22414365 chr20:21694472^21695344 chr6:1378445^1379318 chr8:70981873^70984888 chr12:53107912^53108471 chr10:102996034^102996646 chr3:157821232^157821604 chr4:111554965^111555504 chr13:58206526^58208930 chr10:22634000^22634862 chr9:22005887^22006229 chr5:159399004^159399928 chr2:31805293^31806403 chr6:100903491^100903713 chr5:77268350^77268787 chr14:85997468^85998637 chr5:92923487^92924497 chr11:64480199^64481344 chr13:28366549^28368505 chr5:77805753^77806313 chr9:79633326^79636030 chr4:93226348^93227007 chr2:223170486^223171140 chr1:91172102^91172771 chr1:1181756^1182470 chr8:65281903^65283043 chr10:94825546^94826320 chr6:108491033^108491410 chr21:38076762^38077685 chr1:91183240^91184540 chr3:147136903^147137328 chr15:96911511^96911808 chr14:57274607^57276840 chr13:112726281^112728419 chr2:171672310^171675447 chr8:11559596^11562956 chr10:48438411^48439320 chr18:59000683^59001692 chr15:91642908^91643702 chr5:3592391^3592644 chr19:56988313^56989741 chr6:26614013^26614851 chr11:27742059^27742273 chr3:147113608^147114479 chr14:57264638^57265561 chr7:155302253^155303158 chr11:31848487^31848776 chr16:54970301^54972846 chr19:30715549^30715753 chr9:96710811^96711717 chr18:77557780^77558948 chr20:21686199^21687689 chr11:31847132^31847958 chr16:86530747^86532994 chr1:203044722^203045390 chr15:53096014^53096482 chr7:97361132^97363018 chr14:29236835^29237832 chr13:79182859^79183880 chr11:69517840^69519929 chr1:231296559^231297345 chr19:8675333^8675699 chr1:63795363^63796140 chr4:90228714^90229010 chr3:62362610^62363082 chr19:5827754^5828405 chr10:125732220^125732843 chr9:136293566^136294160 chr1:63782394^63790471 chr4:4867386^4867673 chr9:133534534^133542394 chr15:100913438^100914022 chr10:101279941^101280382 chr13:53419897^53422872 chr1:77747314^77748224 chr14:36974548^36975425 chr12:57618769^57619402 chr7:49813008^49815752 chr4:188916605^188916876 chr11:31831620^31839038 chr8:132052203^132054749 chr2:237071794^237078762 chr20:39994545^39995810 chr11:132812662^132813075 chr5:170735169^170739863 chr1:221051966^221053673 chr5:72529099^72529976 chr14:36973169^36973740 chr4:158141404^158141836 chr14:103655241^103655928 chr1:65731411^65731849 chr1:38218190^38218977 chr3:128719865^128721245 chr15:33009530^33011696 chr2:162275161^162275596 chr7:155241323^155243757 chr19:46001830^46002686 chr6:137814355^137815202 chr7:70596228^70598382 chr15:96959341^96960531 chr16:66612749^66613412 chr6:110299365^110301267 chr15:27215951^27216856 chr11:88241710^88242562 chr2:124782252^124783255 chr17:70111979^70112308 chr2:63283936^63284147 chr17:46800945^46801288 chr6:1393049^1394170 chr3:137489594^137491004 chr15:60296135^60298520 chr12:106979429^106981086 chr12:54360374^54360660 chr14:36991594^36992488 chr4:156129168^156130209 chr4:54975387^54976202 chr3:137482964^137484454 chr10:118893527^118894432 chr18:76737005^76741244 chr10:110671724^110672326 chr5:71014917^71015715 chr6:50787286^50788091 chr19:3868586^3869217 chr4:5894071^5895116 chr11:131780328^131781532 chr6:101846766^101847135 chr11:71952112^71952528 chr5:172663616^172664584 chr9:23822412^23822667 chr4:5891981^5892365 chr1:217310749^217311178 chr10:108923780^108924805 chr6:100038655^100039477 chr7:121945345^121946235 chr3:147126988^147128999 chr7:121956543^121957341 chr4:156680095^156681386 chr4:85404986^85405252 chr1:221064889^221065600 chr17:73749618^73750178 chr8:55370170^55372525 chr6:70992040^70992912 chr16:55513220^55513526 chr6:106433984^106434459 chr14:29254365^29255069 chr6:33655966^33656238 chr9:19788215^19789288 chr11:115630398^115631117 chr1:34628783^34630976 chr14:101923575^101925995 chr17:72855621^72858012 chr2:223162946^223163912 chr4:85417659^85420799 chr1:156390403^156391581 chr3:147130342^147130577 chr2:119602616^119604486 chr9:120175253^120177496 chr4:174443365^174443948 chr5:145724294^145724551 chr11:32454874^32457311 chr2:176949511^176949795 chr1:18436551^18437673 chr3:26665950^26666164 chr3:170303044^170303249 chr2:223176493^223177515 chr2:182321761^182323029 chr18:44789742^44790678 chr17:46796234^46797292 chr18:44772992^44775577 chr8:101117922^101118693 chr7:27134097^27134303 chr10:102507482^102509646 chr19:39754973^39756540 chr7:26415746^26416891 chr14:37116188^37117628 chr4:174421347^174421559 chr6:85472702^85474132 chr20:22557517^22559240 chr6:117198089^117198705 chr10:71331926^71333392 chr19:36334994^36335321 chr4:46995128^46995872 chr9:135455164^135458586 chr8:65290108^65290946 chr10:94828102^94829040 chr1:116380359^116382364 chr15:47476369^47477499 chr3:147115764^147116421 chr17:59485573^59485780 chr10:23983366^23984978 chr2:176949993^176950336 chr9:137967110^137967727 chr2:176957054^176958279 chr11:119293320^119293943 chr11:132813562^132814395 chr2:237068071^237068834 chr10:27547668^27548402 chr4:4866438^4866813 chr21:19617098^19617874 chr1:91185156^91185577 chr19:15292399^15292632 chr1:145075483^145075845 chr2:19560963^19561650 chr14:57260878^57262123 chr8:55378928^55380186 chr6:99290279^99290771 chr19:13124959^13125259 chr15:27112030^27113479 chr8:145925410^145926101 chr11:124629723^124629926 chr4:109093038^109094546 chr3:62356773^62357315 chr14:37131181^37132785 chr10:124905634^124906161 chr7:35296921^35298218 chr19:36248979^36249307 chr12:15475318^15475901 chr5:87985470^87985810 chr12:54423427^54423712 chr7:96653467^96654199 chr2:45155195^45157049 chr15:96896928^96897301 chr12:58004982^58005351 chr2:176933131^176933449 chr2:176962179^176962487 chr20:25063838^25065525 chr12:5153012^5154346 chr3:154146347^154146965 chr1:165323486^165323811 chr21:38065179^38066185 chr10:119000435^119001530 chr12:45444202^45445386 chr4:158143296^158144053 chr5:76932317^76933523 chr5:172659049^172660277 chr2:223168653^223169008 chr1:248020330^248021252 chr18:904578^909574 chr12:127940451^127940907 chr9:135461934^135462909 chr17:48041282^48043064 chr4:94755786^94756310 chr10:130338695^130338994 chr2:119616133^119616826 chr2:177042751^177043444 chr2:105478600^105479188 chr5:172670829^172671824 chr2:176952695^176953297 chr13:28549839^28550246 chr13:112720564^112723582 chr6:100895773^100896062 chr7:136553854^136556194 chr6:127441553^127441760 chr1:119526782^119527192 chr12:49484920^49485178 chr9:23850910^23851522 chr2:220299483^220300243 chr5:1881924^1887743 chr8:57360585^57360815 chr18:74961556^74963822 chr5:172660720^172661133 chr17:75277317^75278172 chr10:99789614^99791320 chr2:176944087^176948446 chr4:154709512^154710827 chr5:140798757^140799359 chr3:44063314^44063837 chr15:79574830^79575211 chr2:223161531^223161919 chr6:134210639^134211218 chr10:102899177^102899489 chr13:79181944^79182222 chr7:71800757^71802768 chr3:186078710^186080111 chr1:24229115^24229537 chr16:48844551^48845264 chr7:113724924^113727795 chr22:44726724^44727590 chr4:15779998^15780729 chr4:41869174^41869459 chr1:38941919^38942404 chr2:176971706^176972305 chr2:119607378^119607910 chr5:76934581^76935296 chr12:103696090^103696418 chr5:63255044^63255407 chr1:221067447^221068185 chr2:119611296^119611881 chr10:124907283^124911035 chr12:114878143^114879155 chr12:49371690^49375550 chr17:36719544^36719938 chr17:46696553^46696926 chr3:147142181^147142391 chr8:9762661^9764748 chr14:74706188^74708192 chr3:12837992^12838359 chr20:37352130^37357372 chr10:8077829^8078378 chr4:4864456^4864834 chr4:13524062^13526083 chr1:66258440^66258918 chr11:17740789^17743779 chr12:106975195^106975714 chr9:91792662^91793611 chr1:149333785^149334111 chr3:170303532^170303768 chr5:72594147^72595808 chr5:145725286^145725852 chr10:23462224^23463889 chr20:21689758^21690048 chr15:53080458^53083699 chr2:154727906^154728271 chr5:170743178^170744107 chr10:102899822^102900263 chr5:134368578^134370466 chr2:66808568^66809404 chr7:96651963^96652246 chr1:91190489^91192804 chr17:75368688^75370506 chr4:185939222^185942747 chr7:43152020^43153340 chr13:84453664^84453897 chr2:176956504^176956707 chr7:87563342^87564571 chr20:17208550^17208756 chr22:19746924^19747141 chr2:223159725^223160487 chr12:131200509^131200726 chr18:44336183^44337110 chr2:63285949^63287097 chr4:13526553^13526770 chr15:89949373^89951130 chr19:55815940^55816277 chr17:50235175^50236466 chr19:58545115^58545897 chr12:113592203^113592620 chr12:115109503^115110061 chr4:164264821^164265772 chr1:2772126^2772665 chr3:71834068^71834653 chr12:5018585^5021171 chr15:74419870^74423044 chr3:147108511^147111703 chr5:88185224^88185589 chr12:54354529^54355491 chr10:101290625^101291178 chr8:11557852^11558252 chr8:105478672^105479340 chr11:20181200^20182325 chr19:54483021^54483572 chr13:112707804^112708696 chr16:22824616^22826459 chr4:66536065^66536674 chr4:154713537^154714240 chr7:12151220^12151559 chr12:119212110^119212393 chr17:14201726^14202052 chr20:21376358^21378245 chr13:36045931^36046143 chr15:60287107^60287663 chr9:100613938^100614622 chr10:102475276^102475579 chr7:121940006^121940648 chr5:37834671^37835128 chr1:197887088^197887791 chr12:99139386^99139769 chr6:1619093^1621094 chr12:113917394^113918107 chr14:24044886^24046760 chr5:77253832^77254049 chr4:85403830^85404524 chr6:166666837^166667541 chr18:77547965^77549038 chr2:219848919^219850541 chr17:7832532^7833164 chr5:134363092^134365146 chr10:103043990^103044480 chr8:97171805^97172022 chr20:57089460^57090237 chr12:114840853^114841063 chr4:66535193^66535620 chr8:85096759^85097247 chr6:10881846^10882051 chr13:28498226^28499046 chr1:161695637^161697298 chr11:2890388^2891337 chr17:5000369^5001205 chr13:27334226^27335205 chr10:22623350^22625875 chr2:157185557^157186355 chr7:20370003^20371504 chr4:961347^962155 chr12:49485766^49485977 chr3:62356119^62356378 chr11:14995128^14995908 chr12:53359192^53359507 chr16:51168266^51169110 chr14:57278709^57279116 chr6:37616722^37617179 chr18:11750953^11752756 chr19:45260352^45261809 chr1:119531991^119532196 chr19:36523391^36523887 chr12:52652018^52652743 chr8:49468683^49468959 chr8:9760750^9761643 chr7:19146923^19147308 chr13:32889533^32889900 chr5:140797162^140797701 chr21:42218489^42219222 chr19:54411376^54411968 chr3:62354291^62355012 chr12:113590806^113591304 chr1:225865068^225865328 chr7:130790358^130792773 chr15:53076187^53077926 chr1:214158726^214159080 chr12:3308812^3310270 chr1:39044059^39044561 chr10:119312766^119313563 chr12:65514878^65515863 chr12:54366815^54369103 chr12:114885105^114885418 chr16:2228190^2230946 chr11:68622722^68623252 chr2:25499763^25500429 chr5:172661486^172662228 chr17:46691520^46692097 chr12:75602991^75603344 chr2:80531367^80531719 chr5:158478378^158478630 chr2:177017266^177017489 chr2:63282514^63283122 chr7:155595692^155599414 chr5:172665306^172666072 chr12:114843022^114843610 chr13:112758598^112760491 chr4:4858389^4858893 chr16:55365814^55366022 chr9:96108466^96108992 chr12:3475010^3475654 chr9:86152353^86153777 chr6:10384965^10385492 chr22:31500396^31501239 chr5:179228283^179229003 chr6:137816474^137817223 chr2:106681982^106682403 chr14:95239375^95239679 chr7:154001964^154002281 chr1:1476093^1476669 chr15:89904822^89906050 chr11:89224416^89224718 chr9:100615234^100617510 chr3:172165372^172166738 chr1:202678881^202679769 chr14:37053134^37053690 chr4:41875445^41875794 chr2:162273294^162273725 chr1:181287300^181287873 chr13:79181327^79181614 chr8:145103285^145108027 chr22:42305617^42307254 chr8:102505512^102506430 chr17:74533281^74534566 chr1:214156000^214156851 chr20:2780978^2781497 chr4:4861227^4862241 chr19:13215244^13215543 chr7:121943867^121944538 chr17:71948478^71949255 chr2:127413696^127414171 chr1:113286332^113287172 chr1:47009575^47010132 chr16:62069121^62070634 chr16:3013651^3015131 chr18:76732970^76734765 chr4:155664819^155665833 chr6:72298274^72298528 chr15:89147660^89149198 chr17:33775294^33775794 chr18:44337510^44338100 chr10:8076002^8077261 chr13:112717125^112717421 chr15:89914363^89915061 chr1:228785986^228786204 chr1:156358050^156358252 chr7:751712^752150 chr3:137489051^137489409 chr17:7905927^7907445 chr18:35144907^35147628 chr3:9177691^9178189 chr6:10390888^10391098 chr14:37052537^37052838 chr1:47909712^47911020 chr13:93879245^93880877 chr1:50893468^50893745 chr7:27282086^27283136 chr4:147558231^147558583 chr19:13124569^13124788 chr17:46619087^46619314 chr3:44596535^44597018 chr14:24803678^24804353 chr2:3286324^3286530 chr12:14134626^14135242 chr12:114881649^114881937 chr20:22548967^22549720 chr8:37822486^37824008 chr13:100641334^100642188 chr4:206377^206892 chr3:11034446^11035384 chr7:152622343^152623305 chr10:22629360^22630328 chr4:140201064^140201449 chr19:46318490^46319266 chr3:121902742^121903645 chr9:77112712^77113583 chr2:114256775^114258043 chr10:15761423^15762101 chr1:115880167^115881332 chr6:50791110^50791573 chr6:55039170^55039392 chr2:176980765^176981423 chr8:86350765^86351196 chr8:24812946^24814299 chr7:19184818^19185033 chr5:76936126^76936984 chr5:87980878^87981272 chr9:77111778^77112042 chr11:20622720^20623399 chr1:50882433^50882660 chr17:35291899^35300875 chr17:46675044^46675589 chr20:5296266^5297798 chr7:156871054^156871297 chr4:681313^681514 chr2:177039551^177039951 chr17:46695325^46695553 chr1:41283840^41284591 chr9:16726859^16727273 chr1:65991001^65991811 chr1:181452706^181453073 chr8:120428398^120429178 chr3:32863174^32863415 chr4:134069162^134070442 chr12:123754049^123754373 chr5:63256548^63257886 chr5:1879689^1879928 chr10:118899247^118900329 chr20:2731063^2731395 chr5:134385967^134386370 chr2:177014948^177015214 chr1:67218079^67218293 chr11:65408344^65408631 chr7:156801418^156801632 chr18:54788959^54789194 chr2:220173870^220174283 chr2:220173021^220173271 chr12:113908887^113910681 chr6:100897080^100897621 chr1:155290606^155291001 chr2:130763483^130763764 chr12:129337870^129338653 chr21:34395128^34400245 chr12:52115410^52115679 chr3:126113547^126113967 chr16:3220438^3221356 chr1:119543056^119543454 chr14:62279476^62280019 chr11:636906^640628 chr10:102893660^102895059 chr3:3840513^3842772 chr1:119529819^119530712 chr9:32782936^32783625 chr19:1064897^1065191 chr5:54527319^54527760 chr7:156795355^156799394 chr1:155147185^155147444 chr9:37002489^37002957 chr11:69831571^69832484 chr2:128421719^128422182 chr22:38476836^38478839 chr19:54412710^54413087 chr9:123656750^123656972 chr7:129422997^129423355 chr19:36336275^36337138 chr2:50574045^50574817 chr10:102975969^102978096 chr6:5996185^5996486 chr3:26664104^26664796 chr7:155170623^155170939 chr8:65286067^65286659 chr14:37125219^37125661 chr11:65816404^65816665 chr6:41908745^41909711 chr17:46620367^46621373 chr2:142887724^142888553 chr1:221050448^221050864 chr12:106974412^106974951 chr14:57278068^57278287 chr1:67773329^67773767 chr17:40936445^40936668 chr20:2729997^2730797 chr12:113013099^113013529 chr7:155244046^155244357 chr1:214153214^214153668 chr1:156863415^156863711 chr1:114695136^114696672 chr14:85996494^85996958 chr7:100823307^100823701 chr20:52789252^52790986 chr5:178421225^178422337 chr11:36397926^36399398 chr13:36052553^36053119 chr14:57283967^57284558 chr4:25090106^25090510 chr2:5831187^5831413 chr6:117869097^117869530 chr19:58094739^58095764 chr4:85422929^85423190 chr13:100547172^100547431 chr8:68864584^68864946 chr16:49311413^49312308 chr7:19184221^19184686 chr2:19562749^19562965 chr19:54481412^54481955 chr10:124901907^124902617 chr3:62357639^62359774 chr11:31827696^31827921 chr17:43037166^43037740 chr7:37955622^37956555 chr6:106429111^106429772 chr6:50682334^50683214 chr5:76923887^76924502 chr6:168841818^168843100 chr7:19145872^19146256 chr20:32856659^32857248 chr17:79859808^79860963 chr7:95225503^95226194 chr14:105167663^105168129 chr17:14248391^14248721 chr16:84002269^84002860 chr9:104499849^104501076 chr17:46604362^46604881 chr2:87015974^87018182 chr14:36990873^36991209 chr5:52777788^52777996 chr19:35633847^35634629 chr1:221055492^221055800 chr1:146551476^146551764 chr13:100642774^100643094 chr14:85999532^86000478 chr13:36049570^36050159 chr2:119606038^119606313 chr11:123065426^123066184 chr3:172167526^172167866 chr4:41882450^41882964 chr8:142528185^142529029 chr9:79637814^79638169 chr3:19189688^19190100 chr4:122301567^122302290 chr10:130339526^130339777 chr9:35846310^35846638 chr15:53097561^53098476 chr2:157184389^157184632 chr5:145718289^145720095 chr11:105481126^105481422 chr5:170741603^170742751 chr3:62355315^62355534 chr1:38219702^38220012 chr4:41881177^41881418 chr13:112715359^112716234 chr17:1880789^1881116 chr18:56887091^56887665 chr6:10390038^10390565 chr11:69516931^69517218 chr19:39737689^39739288 chr3:157812053^157812764 chr14:37049333^37051726 chr7:156409023^156409294 chr11:46366876^46367101 chr5:50685453^50686148 chr4:41883492^41884570 chr13:112709884^112712665 chr22:44287497^44288061 chr22:46440393^46441019 chr8:23562475^23565175 chr2:207506774^207507422 chr4:169799086^169799625 chr3:133393118^133393657 chr8:41424341^41425300 chr4:100870377^100871994 chr4:107956555^107957453 chr17:79314962^79320653 chr2:30453566^30455655 chr1:18956895^18959829 chr12:41086522^41087102 chr22:42685894^42686095 chr6:100914946^100915245 986 chr1:46951168^46951792 987 chr4:41749184^41749811 988 chr11:128419198^128419513 989 chr2:171671598^171671804 990 chr1:170630456^170630851 991 chr20:44657463^44659243 992 chr9:139096665^139096993 993 chr7:155174128^155175248 994 chr14:36993488^36994488 995 chr3:138654837^138655363 996 chr4:5709985^5710495 997 chr15:23157794^23158624 998 chr20:9496471^9496893 999 chr4:174437914^174438346 1000 chr5:140305712^140307193 1001 chr15:79576059^79576270 1002 chr14:38678245^38680937 1003 chr10:102473206^102474026 1004 chr17:59486727^59487132 1005 chr3:64253533^64253819 1006 chr10:102484200^102484476 1007 chr7:27198182^27198514 1008 chr2:97192977^97193383 1009 chr9:77113709^77113927 1010 chr6:154360586^154361008 1011 chr11:44324875^44325087 1012 chr2:182521221^182521927 1013 chr7:124404700^124406189 1014 chr2:132182327^132183101 1015 chr7:101005899^101007443 1016 chr7:149744402^149746469 1017 chr8:50822270^50822860 1018 chr7:27227520^27229043 1019 chr6:134212690^134213098 1020 chr13:36044844^36045481 1021 chr11:132934059^132934291 1022 chr16:51189800^51190260 1023 chr1:155145342^155145938 1024 chr4:682724^683079 1025 chr5:92939795^92940216 1026 chr10:134597357^134602649 1027 chr1:200009807^200010036 1028 chr19:12666243^12666682 1029 chr9:97401286^97402067 1030 chr2:107103833^107104053 1031 chr15:89910521^89912177 1032 chr5:140789094^140789762 1033 chr2:114033359^114033617 1034 chr17:12568667^12569335 1035 chr11:68622108^68622339 1036 chr1:160340604^160340843 1037 chr7:103085710^103086132 1038 chr15:76628998^76629207 1039 chr20:10198135^10198984 1040 chr20:44660342^44660948 1041 chr17:35290403^35290663 1042 chr17:933026^933236 1043 chr4:128544031^128544903 1044 chr1:50881884^50882103 1045 chr10:125425495^125426642 1046 chr17:46801784^46802071 1047 chr1:25255527^25259005 1048 chr3:32861141^32861429 1049 chr17:70116274^70119998 1050 chr10:75407413^75407706 1051 chr2:467849^468659 1052 chr11:132952538^132953307 1053 chr3:6904133^6904641 1054 chr10:120353692^120355821 1055 chr7:20830567^20830817 1056 chr11:71950815^71951408 1057 chr14:95240083^95240341 1058 chr19:5829048^5829474 1059 chr20:9495253^9495597 1060 chr9:112083333^112083549 1061 chr15:96873408^96877721 1062 chr16:67208067^67208678 1063 chr1:175568376^175568808 1064 chr6:5999149^5999787 1065 chr3:129693127^129694841 1066 chr6:10383525^10384114 1067 chr11:636435^636668 1068 chr1:181451311^181452049 1069 chr9:135464586^135466240 1070 chr15:60289325^60289533 1071 chr16:49309123^49309353 1072 chr1:243646394^243646888 1073 chr12:54071053^54071265 1074 chr1:91176404^91176701 1075 chr5:140864527^140864748 1076 chr4:47034427^47034940 1077 chr10:102489343^102491011 1078 chr10:102419147^102419668 1079 chr12:81471569^81472119 1080 chr6:50813314^50813699 1081 chr5:158526133^158526431 1082 chr1:119543821^119544339 1083 chr5:77140542^77140914 1084 chr8:23567180^23567678 1085 chr1:41831976^41832542 1086 chr2:139537692^139538650 1087 chr7:100075303^100075551 1088 chr2:176969217^176969895 1089 chr7:27284639^27286237 1090 chr5:31193952^31194419 1091 chr6:37616393^37616621 1092 chr19:1748167^1750243 1093 chr10:101281181^101282116 1094 chr21:31311386^31312106 1095 chr2:176973427^176973718 1096 chr15:96900142^96900644 1097 chr7:158936507^158938492 1098 chr3:63263989^63264205 1099 chr16:71459781^71460338 1100 chr7:155601175^155603235 1101 chr12:54447744^54448091 1102 chr12:53491572^53491955 1103 chr10:16561604^16563822 1104 chr11:133994709^133995090 1105 chr2:137522460^137523696 1106 chr17:12877270^12877773 1107 chr8:98289604^98290404 1108 chr4:185937242^185937750 1109 chr3:185911344^185912228 1110 chr12:54378696^54380102 1111 chr1:221060850^221061071 1112 chr12:63543636^63544967 1113 chr6:6006689^6007043 1114 chr19:51169659^51172023 1115 chr1:1474962^1475220 1116 chr14:54418677^54418881 1117 chr6:108497595^108497996 1118 chr17:37764092^37764304 1119 chr4:109092578^109092839 1120 chr1:91182097^91182364 1121 chr13:112760865^112761113 1122 chr12:122018170^122018457 1123 chr7:142494563^142495248 1124 chr13:58203586^58204322 1125 chr1:92945907^92952609 1126 chr12:106977388^106977713 1127 chr5:76925445^76926875 1128 chr16:3190765^3191389 1129 chr1:12123488^12124148 1130 chr17:48545570^48546900 1131 chr12:113916433^113916717 1132 chr4:41747508^41747944 1133 chr19:46916587^46916862 1134 chr15:49254984^49255564 1135 chr19:8674332^8674764 1136 chr2:223167205^223167560 1137 chr17:1173535^1174733 1138 chr3:75955759^75956308 1139 chr5:115697134^115697589 1140 chr8:21644908^21647845 1141 chr5:59189046^59189894 1142 chr12:54338761^54339168 1143 chr16:31053479^31053800 1144 chr1:50892437^50893243 1145 chr17:40935964^40936180 1146 chr19:44203558^44203987 1147 chr4:81109887^81110460 1148 chr1:2979275^2980758 1149 chr16:49872449^49872926 1150 chr1:200008392^200009047 1151 chr16:49316997^49317263 1152 chr2:114034594^114036041 1153 chr2:105480197^105480760 1154 chr18:44777632^44778084 1155 chr19:13213450^13213821 1156 chr17:6616422^6617471 1157 chr14:36977518^36977996 1158 chr1:214160798^214161034 1159 chr1:91182509^91182857 1160 chr10:130508443^130508658 1161 chr2:154728944^154729328 1162 chr15:89952271^89953061 1163 chr18:55102427^55102708 1164 chr22:31198491^31199033 1165 chr10:50821487^50821688 1166 chr7:100076454^100076785 1167 chr18:13641584^13642415 1168 chr18:13868532^13869026 1169 chr6:168841438^168841699 1170 chr1:61515875^61516831 1171 chr7:32110063^32110910 1172 chr7:56355508^56355798 1173 chr19:12767749^12767980 1174 chr19:19371675^19372393 1175 chr14:69256676^69257036 1176 chr17:75447477^75447821 1177 chr14:24801680^24802153 1178 chr5:148033472^148034080 1179 chr10:125650820^125651373 1180 chr11:43568921^43569854 1181 chr22:37212769^37213467 1182 chr2:162283581^162284677 1183 chr8:130995921^130996149 1184 chr11:70508328^70508617 1185 chr16:88943427^88943669 1186 chr19:42891311^42891646 1187 chr15:53079220^53079579 1188 chr17:46690390^46691055 1189 chr4:41880224^41880500 1190 chr1:156105707^156106171 1191 chr6:5997027^5997414 1192 chr1:18964180^18964401 1193 chr14:36983440^36983738 1194 chr12:54445876^54446113 1195 chr5:87968635^87968907 1196 chr1:29587087^29587412 1197 chr11:60718428^60718888 1198 chr2:66672431^66673636 1199 chr4:81119095^81119391 1200 chr10:76573195^76573507 1201 chr22:42322043^42322909 1202 chr19:45898879^45900315 1203 chr14:95826675^95826941 1204 chr17:48194634^48195085 1205 chr19:49669275^49669552 1206 chr15:96897596^96898046 1207 chr19:40314926^40315144 1208 chr9:120507227^120507642 1209 chr5:145722467^145722925 1210 chr3:19188246^19188772 1211 chr5:140787447^140788044 1212 chr19:50881418^50881664 1213 chr10:102896342^102896665 1214 chr7:53286851^53287192 1215 chr15:89903446^89903720 1216 chr10:23461300^23461610 1217 chr2:127783081^127783311 1218 chr11:72532612^72533774 1219 chr2:119605200^119605620 1220 chr18:12254147^12255089 1221 chr7:100817759^100817975 1222 chr14:77736733^77737772 1223 chr12:127212279^127212529 1224 chr2:119606569^119606826 1225 chr1:155264318^155265536 1226 chr12:131199824^131200157 1227 chr1:91300979^91301891 1228 chr6:100909210^100909444 1229 chr6:4079052^4079443 1230 chr2:233251361^233253414 1231 chr4:960505^960836 1232 chr19:21769189^21769786 1233 chr10:102279162^102279730 1234 chr12:127210778^127211651 1235 chr12:54069625^54070177 1236 chr15:53087211^53087488 1237 chr13:28365545^28365785 1238 chr12:113913615^113914322 1239 chr14:51338712^51339146 1240 chr7:155604725^155605095 1241 chr3:62364017^62364316 1242 chr6:6008857^6009299 1243 chr3:46618307^46618669 1244 chr17:33776553^33776888 1245 chr12:58158855^58160000 1246 chr2:219857682^219858917 1247 chr19:44278273^44278777 1248 chr10:101282725^101282934 1249 chr20:2539133^2539877 1250 chr12:58003880^58004249 1251 chr16:51147490^51147944 1252 chr1:179544720^179545307 1253 chr2:71787430^71787897 1254 chr10:129534410^129537366 1255 chr6:42145847^42146053 1256 chr14:24802927^24803159 1257 chr22:29707479^29707797 1258 chr9:132459587^132460017 1259 chr17:40937258^40937480 1260 chr4:151504011^151505085 1261 chr1:18967251^18968119 1262 chr19:56598038^56600296 1263 chr19:35633409^35633697 1264 chr2:171678546^171680358 1265 chr6:134638797^134639021 1266 chr1:36549554^36549965 1267 chr19:12833104^12833574 1268 chr3:137487429^137488021 1269 chr9:139715663^139716441 1270 chr6:37617863^37618147 1271 chr17:32484007^32484280 1272 chr7:156409577^156409865 1273 chr5:11384681^11385521 1274 chr8:102504478^102504841 1275 chr20:33296514^33298242 1276 chr20:57415135^57417153 1277 chr10:71331449^71331691 1278 chr3:75667777^75669067 1279 chr16:67571252^67572728 1280 chr19:36500169^36500530 1281 chr2:154729613^154729918 1282 chr12:48399168^48399372 1283 chr4:41867385^41867586 1284 chr17:46800533^46800746 1285 chr20:44685771^44687610 1286 chr19:10406934^10407342 1287 chr6:108496715^108497320 1288 chr5:158523906^158524598 1289 chr9:124413512^124414193 1290 chr20:57427691^57427995 1291 chr16:10912159^10912719 1292 chr7:149389654^149389976 1293 chr1:173638662^173639045 1294 chr19:55597977^55598887 1295 chr14:62279037^62279339 1296 chr3:13114627^13115245 1297 chr2:3750828^3751927 1298 chr4:85402764^85403175 1299 chr17:74017769^74018658 1300 chr5:54523676^54523901 1301 chr7:89747892^89749036 1302 chr18:72916107^72917233 1303 chr9:136294738^136295236 1304 chr1:201252452^201253648 1305 chr5:146888750^146889840 1306 chr14:52734207^52735486 1307 chr13:20875518^20876214 1308 chr18:77560088^77560292 1309 chr2:102803672^102804556 1310 chr2:176982107^176982402 1311 chr17:6679205^6679710 1312 chr19:10463626^10464378 1313 chr5:140810494^140812617 1314 chr11:46299544^46300216 1315 chr11:64136814^64138187 1316 chr6:6007387^6007797 1317 chr17:37321482^37322099 1318 chr10:94455524^94455896 1319 chr13:51417371^51418149 1320 chr8:11565217^11567212 1321 chr1:226127112^226127695 1322 chr2:3287874^3288228 1323 chr6:10882926^10883149 1324 chr22:19746155^19746369 1325 chr3:12838471^12838782 1326 chr9:36739534^36739782 1327 chr9:134429866^134430491 1328 chr11:70672834^70673055 1329 chr14:24641053^24642220 1330 chr7:27283408^27283614 1331 chr12:49182421^49182658 1332 chr1:44031286^44031853 1333 chr1:114696886^114697185 1334 chr15:89901914^89902785 1335 chr11:65352231^65353134 1336 chr7:72838383^72838815 1337 chr22:38379093^38379964 1338 chr4:155663809^155664315 1339 chr9:100619984^100620192 1340 chr7:143582125^143582610 1341 chr7:23287221^23287508 1342 chr11:64815040^64815722 1343 chr2:87088816^87089037 1344 chr20:57426729^57427047 1345 chr10:43428167^43429460 1346 chr10:121577529^121578385 1347 chr4:190939801^190940591 1348 chr6:100037323^100037544 1349 chr19:12880574^12880888 1350 chr2:171670110^171670549 1351 chr7:124404174^124404432 1352 chr7:97840559^97840845 1353 chr19:50879606^50880094 1354 chr1:113265573^113265787 1355 chr19:2424005^2427983 1356 chr3:127633993^127634588 1357 chr10:50817095^50817309 1358 chr2:171676552^171676980 1359 chr1:86621278^86622871 1360 chr1:164545540^164545917 1361 chr22:19967279^19967808 1362 chr11:67350928^67351953 1363 chr20:36226617^36226841 1364 chr19:14089570^14089796 1365 chr19:38700333^38700577 1366 chr1:18435566^18435904 1367 chr8:21905461^21905757 1368 chr2:176950595^176950846 1369 chr17:75251958^75252180 1370 chr15:37390175^37390380 1371 chr9:98113447^98113662 1372 chr1:40235767^40237190 1373 chr8:144811237^144811446 1374 chr8:99984584^99985072 1375 chr7:152621916^152622149 1376 chr1:40769186^40769871 1377 chr19:2428349^2428731 1378 chr17:15820620^15821325 1379 chr22:25081850^25082112 1380 chr1:19203874^19204234 1381 chr20:61703526^61704022 1382 chr2:237080188^237080432 1383 chr1:156338758^156339251 1384 chr1:149332993^149333389 1385 chr22:50496441^50497393 1386 chr7:27146069^27146600 1387 chr13:100547633^100548911 1388 chr4:190939007^190939274 1389 chr7:73894815^73895110 1390 chr19:35632356^35632572 1391 chr16:67918679^67918909 1392 chr2:108602824^108603467 1393 chr2:238864315^238865170 1394 chr8:144808221^144810978 1395 chr8:145101631^145101834 1396 chr12:132905449^132906206 1397 chr6:99275763^99276038 1398 chr5:140800760^140801072 1399 chr17:75242871^75243613 1400 chr17:41278134^41278460 1401 chr12:122016170^122017693 1402 chr10:131264948^131265710 1403 chr17:46631800^46632212 1404 chr14:105167277^105167501 1405 chr10:23982382^23982589 1406 chr19:50931270^50931638 1407 chr3:27771638^27771942 1408 chr18:74799144^74800038 1409 chr1:21616380^21617101 1410 chr1:147782066^147782473 1411 chr7:6590563^6590957 1412 chr7:97839862^97840222 1413 chr12:113914440^113914657 1414 chr19:7933263^7934898 1415 chr20:22559553^22560001 1416 chr15:53086629^53086858 1417 chr10:94180315^94180754 1418 chr5:140052059^140053381 1419 chr10:101287162^101287920 1420 chr14:38677154^38677787 1421 chr22:39262338^39263211 1422 chr18:74153239^74155073 1423 chr15:59157045^59157594 1424 chr4:963804^964115 1425 chr11:624780^625053 1426 chr7:1362811^1363643 1427 chr19:36246328^36247982 1428 chr5:54528095^54528404 1429 chr12:54359658^54359906 1430 chr2:127782613^127782829 1431 chr19:406131^406611 1432 chr17:46697413^46697701 1433 chr18:43608140^43608510 1434 chr16:23724270^23724775 1435 chr18:55922987^55924068 1436 chr15:60291879^60292167 1437 chr14:92788913^92789204 1438 chr19:1108394^1109610 1439 chr11:124628367^124629590 1440 chr1:32052471^32052771 1441 chr19:11594372^11594987 1442 chr19:870774^871318 1443 chr2:54086776^54087266 1444 chr2:241459632^241460047 1445 chr7:127990926^127992616 1446 chr1:208132327^208133117 1447 chr7:90893567^90896683 1448 chr1:41284847^41285149 1449 chr11:32452144^32452708 1450 chr5:77146998^77147785 1451 chr19:45901452^45901688 1452 chr7:6661875^6662695 1453 chr6:161188084^161188639 1454 chr17:934417^935088 1455 chr11:65409636^65410127 1456 chr17:19883325^19883610 1457 chr18:77549524^77550299 1458 chr1:38461584^38461988 1459 chr19:10464666^10464927 1460 chr17:70120139^70120442 1461 chr7:27147589^27148389 1462 chr2:31806545^31806782 1463 chr11:119292689^119292891 1464 chr19:18979351^18981200 1465 chr6:42879279^42879623 1466 chr12:130908777^130909191 1467 chr17:46629553^46629816 1468 chr1:202162958^202163390 1469 chr17:21367114^21367592 1470 chr16:84001805^84002011 1471 chr1:221057463^221057757 1472 chr17:27899511^27900067 1473 chr15:40268581^40269061 1474 chr22:37465056^37465331 1475 chr17:77805866^77809046 1476 chr19:13198699^13198999 1477 chr3:184056419^184056671 1478 chr22:37911979^37912258 1479 chr19:19368708^19369681 1480 chr11:64135815^64136381 1481 chr18:77552401^77552603 1482 chr19:58554354^58554587 1483 chr20:57414595^57414896 1484 chr4:190938106^190938848 1485 chr5:172110282^172111166 1486 chr16:68480864^68482822 1487 chr9:139395020^139395287 1488 chr12:113515164^113515970 1489 chr1:221054554^221054888 1490 chr8:144990270^145002135 1491 chr9:131154346^131155923 1492 chr6:150335525^150336278 1493 chr9:115824684^115825033 1494 chr12:54519768^54520457 1495 chr6:35479872^35480154 1496 chr19:3870788^3871043 1497 chr19:48965002^48965792 1498 chr6:35479388^35479678 1499 chr12:52408381^52408675 1500 chr1:221068782^221069159 1501 chr6:46655262^46656738 1502 chr3:55508336^55508708 1503 chr1:39980365^39981768 1504 chr16:3067521^3068358 1505 chr1:1473107^1473342 1506 chr10:105362549^105362827 1507 chr17:46698880^46699083 1508 chr2:198029068^198029438 1509 chr20:17209418^17209622 1510 chr12:49183049^49183282 1511 chr16:58030214^58031633 1512 chr10:94820026^94823252 1513 chr11:725596^726870 1514 chr6:170732119^170732442 1515 chr12:120835586^120835927 1516 chr20:36012595^36013439 1517 chr8:143545445^143546178 1518 chr6:27228100^27228364 1519 chr21:32624144^32624382 1520 chr9:95477296^95477708 1521 chr10:105420685^105421076 1522 chr1:1470604^1471450 1523 chr1:146552328^146552577 1524 chr19:33625467^33625805 1525 chr11:64478843^64479598 1526 chr20:57428308^57428516 1527 chr7:27182613^27185562 1528 chr19:51815157^51815458 1529 chr17:46607804^46608390 1530 chr12:52408860^52409121 1531 chr19:10405924^10406398 1532 chr11:14993452^14993661 1533 chr19:13135317^13136169 1534 chr7:750788^751237 1535 chr1:53742297^53742845 1536 chr1:200010625^200010832 1537 chr5:139138875^139139242 1538 chr17:45949676^45949885 1539 chr3:128722283^128723036 1540 chr15:89312719^89313183 1541 chr9:135039673^135039978 1542 chr19:12831793^12832225 1543 chr20:51589707^51590020 1544 chr20:3145121^3145746 1545 chr8:65710990^65711722 1546 chr11:128694084^128694688 1547 chr2:20870006^20871280 1548 chr19:18977466^18977833 1549 chr3:49947621^49948430 1550 chr6:30139718^30140263 1551 chr12:104697348^104697984 1552 chr10:105361784^105362188 1553 chr6:29894140^29895117 1554 chr4:187219320^187219745 1555 chr15:67073306^67073943 1556 chr2:220412341^220412678 1557 chr6:170730395^170730887 1558 chr9:115822071^115823416 1559 chr1:10764449^10764925 1560 chr17:46627787^46628444 1561 chr19:51601822^51602260 1562 chr19:55814067^55814278 1563 chr6:138745348^138745593 1564 chr9:124987743^124991086 1565 chr22:46318693^46319087 1566 chr16:3013016^3013228 1567 chr4:114900355^114900810 1568 chr19:1063544^1064265 1569 chr19:1110399^1110701 1570 chr7:97841636^97842005 1571 chr8:57359899^57360114 1572 chr17:72915568^72916510 1573 chr1:16860873^16862296 1574 chr17:75398284^75398527 1575 chr9:139397412^139397710 1576 chr6:33393592^33393908 1577 chr6:29595298^29595795 1578 chr12:6438272^6438931 1579 chr3:113160299^113160641 1580 chr1:55505060^55506015 1581 chr11:132951692^132952260 1582 chr4:81118137^81118603 1583 chr19:38876070^38876332 1584 chr19:58549305^58549712 1585 chr17:43472527^43474343 1586 chr9:139396205^139397040 1587 chr16:3192181^3192669 1588 chr6:33048416^33048814 1589 chr7:128555329^128556650 1590 chr19:46915311^46915802 1591 chr6:30095173^30095610 Table 2: Example CGIs

Table 3: Additional Example CGIs Table 4: Additional Example CGIs